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ABSTRACT:
Lung cancer is still the leading cause of cancer death worldwide. Both histologically 
and molecularly lung cancer is heterogeneous. This review summarizes the current 
knowledge of the pathways involved in the various types of lung cancer with an 
emphasis on the clinical implications of the increasing number of actionable molecular 
targets. It describes the major pathways and molecular alterations implicated in the 
development and progression of non-small cell lung cancer (adenocarcinoma and 
squamous cancer), and of small cell carcinoma, emphasizing the molecular alterations 
comprising the specific blueprints in each group. The approved and investigational 
targeted therapies as well as the immune therapies, and clinical trials exploring the 
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Lung cancer is the leading cause of cancer death 
worldwide. Approximately 80% of lung cancers are 
grouped as non-small cell lung carcinoma (NSCLC), 
which are clinically and pathologically different from 
small cell lung carcinoma (SCLC). Adenocarcinoma 
(AC) of lung comprises about 40% to 50% of all lung 
cancers.  AC is the most common subtype of NSCLC, 
the group that also includes squamous cell carcinoma 
(SQCC) and large cell carcinoma (LCLC). Recently, 
genomic-based  classification  of  LCLC  eliminated  this 
subtype, demonstrating that it can be molecularly sub-
classified as either adenocarcinoma or neuroendocrine 
tumor [1]. The discovery of recurrent mutations in EGFR Oncotarget 1393 www.impactjournals.com/oncotarget
and fusions involving ALK and other receptor tyrosine 
kinases (RTKs), and development of targeted therapies, 
have transformed the standard of treatment of patients 
with AC. Molecular genotyping of AC now routinely 
includes testing the status of EGFR and ALK, which are 
altered in about 25% of AC patients, and for which there 
are approved targeted therapies.  Patients with alterations 
in EGFR and ALK respond better to targeted inhibitors 
than to conventional chemotherapy. 
SQCC tumors rarely have mutations in EGFR or 
ALK fusions, instead harboring alterations in other RTKs – 
mutations in DDR2 and amplifications/mutations of FGFR 
(fibroblast growth factor receptor) family, both of which 
are therapeutic targets. Analysis of signaling pathways 
involved in pathogenesis and large-scale genomic analyses 
of SQCC reveal it to be a distinct clinicopathological type 
of NSCLC, even though some somatogenic alterations 
are shared with AC (Tables 1 and 2). SCLC, however, is 
an entirely distinct type of lung cancer, originating in a 
different cellular compartment of lung tissue, and with its 
own distinct molecular pathogenesis as well as pathology 
and clinical course. 
In spite of advances in targeting signaling pathways 
in NSCLC, the most prevalent mutations found in lung 
cancer are those within the tumor suppressor TP53, 
which are currently untargetable. ACs often contain loss-
of-function mutations in other tumor suppressor genes 
– the most prominent, in addition to TP53, being loss of 
function of LKB1/STK11, NF1, CDKN2A, SMARCA4, 
and KEAP1. SQCC tumors have a different and partially 
overlapping with AC spectrum of inactivated tumor 
suppressors: TP53 in a majority of tumors and inactivation 
of any of the following: CDKN2A, PTEN, KEAP1, 
MLL2, HLA-A, NFE2L2, NOTCH1 and RB1. These are 
challenging therapeutic targets, even though strategies 
for indirect targeting, i.e., involving proteins activated in 
the pathways governed by tumor suppressors, are being 
developed.
A number of targets other than EGFR and ALK are 
explored in clinical and preclinical development, and most 
of them are altered in AC in a gain-of-function manner, 
i.e., increase in enzymatic activity that could be targeted. 
Among these targets are KRAS, BRAF, ERBB2, PI3KC 
and translocations involving RET and ROS, as well 
as RTK MET, which is activated mainly in tumors that 
develop resistance to targeted therapies.
A large study employing next generation sequencing 
(NGS) to identify mutations and other alterations in AC 
was conducted in 2012, sequencing exomes or genomes 
of 183 ACs [2].  The mean exomic somatic mutation rate 
in this study was 12 per megabase, but there were large 
differences in numbers of mutations observed in tumors 
from non-smokers versus smokers: mean 2.9/Mb versus 
12.9/Mb. In an earlier smaller study the difference was 
reported to be 10-fold [3].  The authors [2] noted that a 
significant  number  of  driver  mutations  grouped  with 
epigenetic or RNA deregulation, which has not been 
recognized in the pre-genomics era. These are interesting 
observations regarding the pathogenesis of AC but it is 
possible that they could be explained in part by the failure 
to identify all driver mutations.
A large NGS analysis of SQCC (178 tumors) 
performed by the Cancer Genome Atlas Research Network 
identified a mean of 360 exomic mutations, 323 altered 
copy number segments and 165 genomic rearrangements 
per tumor. The mean somatic mutation rate of 8.1 
mutations per megabase observed in this study of SQCC 
was higher than that previously reported for a number 
of other types of cancer.  The spectrum of somatic copy 
number alteration in SQCC was in general similar to AC 
with a notable exception of selective amplification of a 
region on chromosome 3q. The evidence of unique clinical 
and  pathological  character  of  SQCC  was  confirmed 
in  this  study  [4]  that  identified  SOX2  amplification, 
NFE2L2 and KEAP1 mutations, PI3K pathway changes, 
FGFR1 amplification, and DDR2 mutations that are not 
encountered or are relatively rare in AC.
Small cell lung cancer is almost exclusively 
associated with smoking, with about 90% of patients 
being smokers or former smokers.  SCLC patients with 
extensive have a poor prognosis, even though the initial 
response to chemotherapy could be positive. Relapse 
usually occurs within months, and the recurrent disease 
is almost invariably lethal. Integrative genome analysis 
of 29 SCLC tumors [5] has determined an extremely 
high mutation rate of 7.4 protein-changing mutations 
per megabase. It also confirmed that all SCLC tumors 
have inactivated TP53 and RB pathways and recurrent 
amplifications of MYC genes, known to be a hallmark of 
SCLC prior to the evolution of NGS methodologies. In 
addition, the study found recurrent mutations in histone 
modifiers  CREBBP,  EP300,  and  MLL.    Involvement 
of signaling pathways in SCLC is more limited than in 
other lung cancer types, with 6% of tumors carrying 
amplified FGFR1, and PTEN inactivation occurring in 
some tumors. Profound disregulation of cell cycle control 
involving the already mentioned alterations in TP53 and 
in RB1 and MYC genes is a ubiquitous feature of SCLC. 
Disregulation of the developmental pathways was noted 
in about 10% of tumors through mutations in SLIT2 and 
EPHA7. Proteomic profiling identified EZH2 and PARP-1 
as activated and highly expressed proteins in SCLC [6].
This paper will review alterations in a number 
of cellular pathways involved in pathogenesis of lung 
cancer, emphasizing those that contain actionable targets, 
and providing information on clinical testing of relevant 
investigational drugs. Table 1 lists pathways and genes 
products known to be involved in three major types of lung 
cancer, and Table 2 contains a more detailed description of 
gene products and frequency of their alterations as well 
as potential drugs. It is obvious from Table 1 that RTK 
signal transduction pathways are predominantly affected Oncotarget 1394 www.impactjournals.com/oncotarget
in AC, and much less so in SQCC and particularly in 
SCLC, while the PI3K pathway is deregulated in more 
than half of SQCC. SCLC is distinguished by universal 
disruption of both TP53 and RB1 pathways, even though, 
as mentioned, TP53 itself is the most frequently mutated 
gene in all types of lung cancer. Interestingly, epigenetic 
deregulation is observed in all three types with similar 
frequency but involves different sets of genes that are 
mutated. Developmental or differentiation pathways 
are involved most prominently in SQCC and only one 
developmental gene is affected by recurrent mutations in 
AC.
1. Molecular targets in lung cancer
1.1 RECEPTOR TYROSINE KINASES (RTKs) 
RTKs are involved in different types of lung cancer 
at different frequencies, but have attracted a lot of interest 
because there are targeted therapies for activated RTKs 
approved or fairly advanced in clinical development. 
Testing for mutations in EGFR and ALK translocation 
in AC has become a routine diagnostic procedure, in 
line with NCCN guidelines, because treatment of EGFR 
mutant and ALK-positive AC with FDA-approved targeted 
drugs produces better responses than chemotherapy 
regimens. 
EGFR
EGFR is a receptor tyrosine kinase that binds to 
epidermal growth factor and other growth factor ligands 
to become activated. Upon activation, EGFR tyrosine 
kinase activates downstream pathways including MAPK 
and PI3K, leading to DNA synthesis and cell proliferation. 
Activation of EGFR has other pleiotropic effects, among 
them contributing to immune escape of tumors [7] and to   
suppression of autophagy [8], both with serious clinical 
implications for immunotherapy approaches and the 
currently explored therapeutic induction of autophagy, 
respectively.
EGFR is implicated in a variety of cancers and 
frequently mutated in AC. EGFR alterations occur in 
~10% of western and ~50% of Asian patients with lung Oncotarget 1395 www.impactjournals.com/oncotargetOncotarget 1396 www.impactjournals.com/oncotarget
AC. Higher EGFR mutation frequency is observed in non-
smokers, women, and in non-mucinous tumors.  EGFR 
has been shown to be deregulated by various mechanisms 
in  AC,  including  overexpression,  amplification,  and 
mutation. Overexpression of EGFR occurs in up to 60% 
of NSCLC, with higher frequency in AC versus SQCC   
(reviewed in [9, 10]).
Several types of activating mutations are known to 
occur in EGFR in NSCLC: Class I - exon 19 in-frame 
deletions (44% of all EGFR mutations), Class II - single 
amino acid changes (L858R 41%, G719 4%, other 
missense mutations 6%), Class III - exon 20 in-frame 
duplication/insertions (5%). These mutations occur in the 
tyrosine kinase domain of EGFR.  Eighty-five percent 
of all EGFR-activating mutations are exon 19 in-frame 
deletions or L858R, and they tend to be sensitive to 
currently approved EGFR inhibitors (reviewed in [11]). 
Class III mutations (exon 20) are generally insensitive to 
EGFR inhibitors with exception of A763_Y764insFQEA 
[12].
Patients with AC and “large cell” histology NSCLC 
should be tested at diagnosis for EGFR mutations, as 
those who exhibit such mutations benefit from EGFR 
inhibitors (e.g., erlotinib, gefitinib, or afatinib) in the first-
line setting. Data from several clinical trials have indicated 
that patients with EGFR mutations have improved 
progression-free survival (PFS) and overall survival (OS) 
when treated with EGFR inhibitors compared to patients 
with the same mutations who received standard-of-care, 
cytotoxic chemotherapy regimens [13-15]. 
Potential therapeutic approaches for EGFR-
mutant AC
EGFR inhibitors. Table 3 lists many of the 
EGFR inhibitors as well as other targeted drugs 
under development for treatment of NSCLC, and a 
comprehensive list of targeted therapies for NSCLC is 
regularly updated and published [16]. FDA-approved 
EGFR  inhibitors  include  erlotinib  (Tarceva),  gefitinib 
(Iressa) and afatinib (Gilotrif). A randomized trial in 
Japan showed a significantly prolonged PFS in patients 
on gefitinib versus standard chemotherapy [17]. This trial 
was the first randomized study to demonstrate benefit 
of an oral targeted therapy versus chemotherapy in a 
molecularly selected population with NSCLC. However, 
FDA withdrew approval for use of gefitinib in new patients 
due to lack of evidence that it extends life. In May 2013 
FDA approved a companion diagnostic test for erlotinib 
(Cobas) that detects exon 19 deletions or exon 21 L858R 
substitutions. These mutations are found in patients that 
are selectively good responders to erlotinib therapy. In a 
pivotal trial of erlotinib versus chemotherapy, PFS of 13.1 
months was seen with erlotinib treatment, compared to 
4.6 months for those who received a standard two-drug 
chemotherapy regimen [18].
Icotinib is another EGFR inhibitor clinically 
developed in China and reportedly active against mutant 
and wild-type forms of the receptor. A phase 3 randomized 
trial of icotinib versus gefitinib showed the non-inferiority 
of icotinib and a much better profile in terms of drug-
related side effects [19]. 
Second-generation EGFR inhibitors that bind 
to EGFR or other receptors in the EGFR family in an 
irreversible manner are in clinical testing (reviewed 
in [20]). BIBW2992/Afatinib is an irreversible ErbB 
family blocker that covalently binds to the cysteine 
residue of EGFR (as well as HER2), providing longer 
inhibition of EGFR (reviewed in [21]). Afatinib showed 
objective responses in 60% of molecularly selected 
patients in a phase 2 study, LUX-Lung 3 [22]. Afatinib 
has also demonstrated a small benefit in those previously 
treated with other EGFR TKIs [23].  In a decisive large 
randomized trial, afatinib in a preselected EGFR-
mutant population was compared to the state-of-the-art 
chemotherapy with pemetrexed and cisplatin, and was 
shown to be superior [24]. Afatinib is undergoing clinical 
testing as single therapy or in combination treatments 
in at least 20 trials (for example, NCT01542437, 
NCT01466660).  In July 2013 afatinib (Gilotrif) was 
approved as the first-line treatment for advanced stage 
NSCLC with class I and class II EGFR mutations.
Dacomitinib (PF-00299804), a pan-EGFR-family 
irreversible inhibitor is currently in several trials for 
NSCLC, such as phase 2trial NCT01858389 for advanced 
NSCLC, phase 3 NCT01360554 comparing dacomitinib 
and erlotinib, phase 3 NCT01774721/ARCHER 1050 
comparing  dacomitinib  versus  gefitinib,  phase  3 
NCT01000025 for patients with advanced NSCLC who 
have not responded to previous therapies, and several 
more.  In a recent trial, treatment with dacomitinib was 
associated with a median PFS of 12.4 weeks compared 
with 8.3 weeks for erlotinib in patients with AC. However, 
a superior PFS with dacomitinib compared to erlotinib 
was not observed in other histological subtypes of 
NSCLC [25]. All the aforementioned EGFR inhibitors 
are anilinoquinazolines and engage both the mutant and 
wild type receptors. Thus this class of drugs share the 
common side effects of rash and diarrhea which arises by 
the binding of the EGFR receptors in the skin and gastro-
intestinal tract respectively. 
Other EGFR inhibitors are in various stages of 
development. Some of these are pyrimidines and engage 
only the mutant receptor. Therefore this class of drugs 
lack the troublesome rash and diarrhea seen with the 
aniliquinazolines. CO-1686 is an irreversible inhibitor 
of EGFR active in the presence of T790M patients, and 
is now in an early clinical trial involving a selected, 
pretreated patient population with the T790M mutation 
that  confers  resistance  to  first-generation  inhibitors 
(NCT01526928). AP26113, a dual ALK/EGFR inhibitor 
that appears to overcome RTK-mutation-based resistance, Oncotarget 1397 www.impactjournals.com/oncotarget
has entered clinical testing NCT01449461. The trial 
recruits patients with ALK translocation and those 
previously treated with EGFR inhibitors that developed 
T790M mutation. 
Inherent lack of response to EGFR inhibitors is 
not well understood, but presence of mutations in KRAS 
(codon 13) was predictive for poor response to erlotinib 
compared to mutant codon 12 [26]. However, KRAS and 
EGFR mutations are almost always mutually exclusive, 
and the lack of response to EGFR TKIs is most likely 
due to the absence of an EGFR mutation as opposed to 
the existence of a KRAS mutation. Some mutations in 
EGFR, such as insertions in exon 20 [27] and T790M 
(rarely found in untreated AC) confer primary resistance 
to EGFR.
Antibodies. Cetuximab (Erbitux), a chimeric 
monoclonal IgG1 antibody that blocks EGFR signaling, 
has been investigated in the front line in combination 
with platinum-based chemotherapy in advanced 
NSCLC through two multicenter, randomized phase 
3 trials.  Necitumumab and nimozutumab, other anti-
EGFR antibodies, have also been investigated in several 
clinical trials, mostly in combination with chemotherapy 
regimens. A randomized phase 3 trial (SQUIRE) 
comparing chemotherapy (gemcitabine and cisplatin) with 
necitumumab versus chemotherapy alone demonstrated a 
significantly increased overall survival (OS) in patients 
with metastatic stage 4 SQCC (Eli Lilly press release, Aug 
2013). 
Combination Therapies. Over 100 clinical trials 
for recurrent or advanced NSCLC involve erlotinib 
in combination with other therapies. Results of a trial 
using combination of erlotinib and tivantinib/ARQ 
197, a non-ATP-competitive inhibitor of MET, showed 
clinical activity in patients with NSCLC, with 6 of 8 
patients achieving stable disease [28]. One study explored 
combination of erlotinib with HDAC inhibitor entinostat 
in patients with advanced NSCLC that had progressed 
after chemotherapy. Although the combination regimen 
did not demonstrate a significant survival advantage in the 
overall population, it showed a synergistic effect in the 
subset of patients with high E-cadherin expression [29].  A 
phase 1 study of the combination of erlotinib, cetuximab, 
and bevacizumab was well-tolerated and demonstrated 
antitumor activity in heavily pretreated patients with 
NSCLC [30]. A meta-analysis of results of studies of 
erlotinib alone versus combination targeted therapies 
concluded that the latter are superior over erlotinib 
monotherapy as second-line treatment for advanced 
NSCLC [31].
A phase 3 randomized trial explored addition of 
erlotinib to the doublet chemotherapy with cisplatin/
gemcitabine as a - treatment in patients with advanced 
NSCLC.  Addition of erlotinib significantly prolonged PFS 
in patients with mutant EGFR [32].  Addition of afatinib to 
the same regimen of chemotherapy in a randomized phase 
3 trial had a strong positive effect on PFS [24].
There are a number of other trials evaluating the 
efficacy of combining first- or second-generation EGFR 
inhibitors with other molecularly targeted agents. Some 
of ongoing combination therapy trials with erlotinib are:   
NCT01294306 - erlotinib and AKT inhibitor MK2206; 
NCT01859026 - erlotinib and MEK inhibitor MEK162, 
in EGFR and KRAS mutant NSCLC; NCT00994123 
– erlotinib and MM-121, an anti-ERBB3 antibody (see 
below, under ERBB3 section), NCT01454102 – erlotinib 
and nivolumab (anti-PD-1 antibody), NCT00966472 - 
erlotinib with Rosurastatin, NCT01186861 - erlotinib 
and linsitinib/OSI-906 (IGF1R inhibitor); NCT01708954 
- erlotinib with Aurora A inhibitor MLN8237; 
NCT01471964 – erlotinib and mTOR ihnibitor CC-223.   
Afatinib is currently being evaluated in combination with 
nimozutumab (anti-EGFR antibody) in NCT01861223, 
with cetuximab (anti-EGFR antibody) in NCT01090011, 
with the HSP90 inhibitor AUY922 in NCT01259089, 
and with sirolimus/rapamycin (mTOR inhibitor) in 
NCT00993499. 
As already mentioned above, anti-EGFR antibodies 
are also analyzed in combination trials. For example, 
NCT01451632 examines the effects of cetuximab with 
MM-121 (anti-ERBB3 antibody) and chemotherapeutic 
agent irinotecan. Necitumumab is also currently 
being investigated in six trials involving combination 
chemotherapy. 
Resistance to EGFR inhibitors
As noted, EGFR inhibitors have a significantly better 
effect on PFS compared with conventional chemotherapy 
[33]. However, nearly all patients with EGFR-mutant-
AC develop resistance to the first-generation inhibitors 
erlotinib and gefitinib, with a median PFS of 14 months 
[34]. Several mechanisms have been implicated in 
resistance to EGFR inhibitors, and they were reviewed 
recently [35-37].
The most common mechanism of acquired resistance 
to erlotinib or gefitinib is emergence of the “gatekeeper” 
mutation in EGFR itself, which likely indicates the 
“addiction” of lung cancer to EGFR signaling. A single 
amino acid change, T790M in exon 20 of the EGFR gene, 
is found in about 50% to 60% of patients developing 
resistance [38]. EGFR TKIs (such as erlotinib or gefitinib) 
are selective inhibitors of EGFR’s kinase domain, that 
work by competing with ATP at the ATP-binding site, 
thereby preventing autophosphorylation and activation. 
The T790M mutation affects the gatekeeper residue in 
the catalytic-kinase domain and confers drug resistance 
by increasing EGFR’s affinity for ATP – thus reducing the 
potency of the ATP-competitive kinase inhibitors [39]. 
Interestingly, the development of a T790M mutation may 
actually confer a relatively improved survival, as tumors 
that acquire it appear to be less aggressive than tumors Oncotarget 1398 www.impactjournals.com/oncotarget
with EGFR TKI resistance due to other mechanisms [40]. 
The other common mechanism of acquired 
resistance to EGFR tyrosine kinase inhibition involves 
amplification of RTK c-MET [41], a proto-oncogene that 
encodes a protein also known as hepatocyte growth factor 
receptor (HGFR),. Interestingly, a subpopulation of cells 
with amplified MET might preexist in tumors – i.e., MET 
amplification occurs in limited areas prior to treatment 
with EGFR inhibitors [42]. This might be due to increased 
levels of HGF that apparently accelerate development of 
MET amplification in vitro and in vivo [42]. Activation 
of MET promotes epithelial to mesenchymal transition or 
EMT [43]. 
EMT has been heavily implicated in the resistance 
of NSCLC to EGFR inhibitors and could involve 
upregulation of another RTK AXL. AXL drives a 
mesenchymal phenotype, and resulting tumors acquire 
sensitivity to AXL inhibitor SGI-7079 [44]. IGFR-1 could 
also promote EMT in tumors with EGFR mutations, and 
this involves TGFα-1 signaling rather than MET or AXL 
hyperactivaiton [45].
In addition to EMT, PIK3CA mutations, and 
conversion to small cell lung cancer histology are other 
mechanisms that have been implicated in resistance to 
EGFR inhibition [46]. Serial biopsies revealed that these 
genetic mechanisms of resistance were lost in the absence 
of the continued selective pressure of EGFR inhibitor 
treatment, and such cancers were sensitive to a second 
round of treatment with EGFR inhibitors [46]. 
Another mechanism of resistance is amplification of 
HER2 reported to occur in 12% of tumors that developed 
resistance to EGFR inhibitors [47]. HER2 amplification 
and EGFR (T790M) were mutually exclusive in this 
setting. Afatinib (second-generation EGFR inhibitor) and 
cetuximab  (anti-EGFR  antibody)  significantly  inhibit 
HER2 phosphorylation in vitro, suggesting that tumors 
acquiring resistance to erlotinib should be tested for 
HER2 status and potentially treated with a pan-EGFR TKI 
inhibitor such as afatinib [47].
An extensive study examined potential involvement 
of mutations in BRAF, NRAS, KRAS, and MEK1 in a 
large number of resistant tumors, and found no evidence 
of secondary mutations in these genes with the exception 
of BRAF, where mutations were identified in 2 of 195 
(1%) biopsies [48]. However, reduced expression of the 
negative regulator of RAS proteins, NF1, was implicated 
in both intrinsic and acquired resistance to EGFR 
inhibitors that could be rescued with MEK1 inhibitor [49].
Preclinical studies with NSCLC cells selected in 
vitro for resistance to EGFR inhibitions indicated other 
potential mechanisms of acquired resistance, such as 
increased expression of FGF2 and FGFR1, in an autocrine 
bypass loop [50].Another study has identified an acquired 
amplification  of  the  adaptor  protein  CRKL  (that  has 
known oncogenic properties) in an NSCLC patient that 
developed resistance to erlotinib [51]. 
Deubiquitinating enzymes that prevent 
ubiquitination-triggered degradation of RTKs could 
become a new target in forestalling resistance to RTK 
inhibitors. Silencing or pharmacological inhibition of 
USP8 deubiquitinase, relevant in particular to the stability 
of RTKs such as EGFR and MET, was shown to induce 
death of gefitinib-resistant NSCLC cells in vitro and in 
vivo [52].
17-DMAG (Hsp90 inhibitor) and belinostat 
(histone deacetylase inhibitor) alone and particularly in 
combination were shown to be efficacious in a setting of 
resistance to EGFR inhibitors conferred by mutations in 
EGFR or PTEN [53]. These pathways already are and will 
be further interrogated in clinical trials. 
Addressing drug resistance in EGFR mutant 
NSCLC 
Second Generation EGFR Inhibitors. The second-
generation TKIs such as afatinib (BIBW2992) described 
above irreversibly inhibit RTKs of EGFR family, as well 
as the T790M variant of EGFR [21, 54].  As mentioned 
above, afatinib has been evaluated in the LUX-Lung trials, 
with improvement in PFS reported in patients with EGFR-
activating mutations, as both the first- and second/third-
line therapies compared to chemotherapy. But some other 
results indicate limited activity of the second generation of 
EGFR inhibitors in the setting of T790 mutation [55, 56].
The novel inhibitor CO-1686 showed promising 
results in NSCLC patients with the T790M EGFR 
mutation that were previously treated with the first-line 
EGFR inhibitor (erlotinib or gefitinib) (NCT01526928). 
Resistance to CO-1686 was observed in vitro and could 
be overcome with an inhibitor of AKT [57]. AP26113, a 
dual ALK/EGFR inhibitor that also appears to overcome 
T790M-mutation-based resistance, has entered clinical 
testing (NCT01449461) in patients with acquired T790M. 
AZD9291 is another new inhibitor of EGFR including 
T790M variant in clinical development (NCT01802632) 
and has already produced partial responses in patients 
that progressed on other EGFR inhibitors (15th World 
Conference on Lung Cancer, 2013). 
Some evidence indicates that targeting other RTKs 
of the EGFR family in combination with EGFR inhibitors 
might be efficient in preventing development of resistance 
[58]. Clinical trials addressing this possibility are listed 
above, in “Combination Treatments.” In particular, 
targeting ERBB3 is of clinical interest due to its ability to 
strongly activate PI3K signaling.
MET inhibitors. Various drugs or antibodies capable 
of inhibiting MET (e.g., crizotinib, foretinib, ARQ 197, 
MetMAb) could, in principle, be combined with the 
first  (erlotinib)  or  second  (Dacomitinib/PF-00299804, 
afatinib/ BIBW2992) generation EGFR-TKIs. Concurrent 
inhibition of both may improve patient outcomes. Small-Oncotarget 1399 www.impactjournals.com/oncotarget
molecule inhibitors of MET and MetMAb/Onartuzumab 
are currently being tested in NSCLC (see MET section). 
However, the phase III trial of Onartuzumab combined 
with erlotinib in MET positive EGFR mutant NSCLC 
failed to improve PFS or OS in spite of the positive results 
from a phase II trial [59]. 
Hsp90 inhibitors. HSP90 is a molecular chaperone 
that is critical for tumor growth and proliferation.  Many 
cancers have increased levels of active Hsp90, which is 
involved in protein folding. Client proteins of HSP90 
include many signaling kinases such as RTKs and 
intracellular kinases essential for cancer cell survival, 
since lack of HSP90 triggers protein degradation. Hsp90 
inhibitors may thus block multiple signaling pathways 
that are functioning aberrantly in cancer cells.  Hsp90 
inhibitors such as AUY922 and ganetespib (STA9090) 
are in many clinical trials for lung cancer. Both inhibitors 
showed good efficacy in preclinical models of NSCLC 
[60-62]. Ganetespib monotherapy showed clinical activity 
in heavily pretreated patients with advanced NSCLCs, 
particularly in patients with tumors harboring ALK gene 
rearrangement [63]  (see “ALK” section). AUY922 
is currently being evaluated in five trials for NSCLC. 
NCT01784640,  for  example,  addresses  specifically 
efficacy  of  AUY922  with  pemetrexed  in  previously 
treated Stage IV patients. However, HSP90 inhibitors are 
expected to work best in combination with other drugs, 
and a randomized phase 2trial of ganetispib with docetaxel 
showed a significant improvement in overall survival in 
stage 4 patients (ASCO meeting 2013).  A different type 
of inhibitor, OGX-427, an antisense oligonucleotide to 
HSP90, is currently in clinical testing in combination with 
chemotherapy (NCT01829113). 
Combination therapies. A number of trials examining 
combination treatments to forestall or overcome resistance 
to EGFR inhibitors were described above. Ongoing trials 
for recurrent or advanced NSCLC will test the efficacy of 
various combination therapies including EGFR inhibitors, 
second-generation tyrosine kinase inhibitors, dual MET/
VEGFR2 inhibitor, and targeted drugs to different proteins 
disregulated in lung cancer. For example, docetaxel with 
or without the FGFR1 inhibitor AZD4547 is currently 
being tested in both NSCLC and squamous cell carcinoma 
of lung (NCT01824901). NCT01121575 explores 
combination of PF 02341066 (Crizotinib) with the pan-
HER inhibitor PF 00299804. NCT01337765 examines 
MEK and PI3K/mTOR inhibitor combination in patients 
who progressed on EGFR inhibitors.  NCT01487265 
will explore combination of PI3K inhibitor BKM-120 
and erlotinib in patients that previously responded to 
erlotinib but developed resistance. An ongoing phase 1 
trial explores the combination of afatinib with anti-EGFR 
antibody cetuximab in the setting of acquired resistance to 
erlotinib or gefitinib (NCT01090011).
EGFR inhibitors in tumors with wild-type EGFR 
Identification  of  patients  with  wild-type  EGFR 
tumors who may benefit from treatment with an EGFR 
inhibitor is a clinically important question. The two first-
generation EGFR inhibitors differ in their selectivity 
towards tumors with wild-type EGFR. Erlotinib has 
demonstrated activity in pre-treated patients with EGFR 
wild-type tumors [64], with modest improvement in 
survival outcomes as switch-maintenance therapy [65]. 
In contrast, gefitinib has only demonstrated activity in 
patients with activating mutations in EGFR.  Dacomitinib 
showed a superior PFS to erlotinib in patients with wild- 
type (and mutant) EGFR [25]. 
An approved test known as VeriStrat provides 
likely responsiveness to EGFR inhibitory therapies in 
the absence of EGFR mutations. VeriStrat utilizes mass 
spectrometry to evaluate tumor EGFR ligand levels 
and predict patient response and survival outcome to 
erlotinib and other EGFR inhibitors from serum samples 
[66].  Several recent studies have indicated that VeriStrat 
classification has significant power to predict response to 
EGFR inhibitors for several cancer types [67, 68] . The 
“VeriStrat good” patients had increased survival after 
erlotinib treatment compared to the “VeriStrat poor” group 
[69].  A later study found that VeriStrat has a prognostic 
role in patients with advanced, nonsquamous NSCLC 
treated with erlotinib and bevacizumab in the first line 
[70]. 
However, the use of RTK inhibitors in wild-type 
EGFR NSCLC patients remains a subject of controversy, 
with some investigators advocating it [71, 72], while 
others provide data analysis indicating no benefit in this 
large heterogeneous population of patients [73]. A large 
randomized  trial  has  showed  the  superior  efficacy  of 
docetaxel over erlotinib in wild-type EGFR patients [74]. 
It appears that grouping together EGFR wild-type NSCLC 
as a category is misleading, and should be replaced by 
further molecular analysis of these tumors with a goal of 
identifying the clinically important genetic alterations. 
Indeed, the current (2013) ASCO guidelines state: “in 
unselected patients, evidence is insufficient to recommend 
single-agent erlotinib or gefitinib as first-line therapy… if 
EGFR mutation status is negative or unknown, cytotoxic 
chemotherapy is preferred.” 
EML4-ALK
The EML4-ALK oncogene is a fusion between 
echinoderm microtubule-associated protein-like 4 (EML4) 
and anaplastic lymphoma kinase (ALK) [75].  The fusion 
generates an overexpressed and activated tyrosine kinase, 
whereas normal lung tissue does not express ALK.   
EML4-ALK fusions are found in about 3% to13 % of 
NSCLC patients [76], and are largely mutually exclusive Oncotarget 1400 www.impactjournals.com/oncotarget
with alterations in other RTKs or KRAS based on analysis 
of almost 1700 tumors [77]. Patients with EML4-ALK 
mutant tumors are characteristically younger, and like 
patients with EGFR-mutated NSCLC, they typically are 
never smokers with AC histology [78]. 
EML4-ALK oncogene does not involve either PI3K 
or MAPK pathways in its transforming activity, which 
suggests lack of utility of inhibitors of these pathways 
in treating patients with the ALK fusions.  However, 
inhibition of molecular chaperone HSP90 leads to 
degradation of EML4-ALK and a rapid, but transient, 
regression of tumor growth in a mouse model [79].
Potential therapeutic approaches for EML4-ALK
ALK inhibitors. Crizotinib (Xalkori) was approved 
by the FDA for ALK-positive NSCLC in 2011. A large 
phase 3 trial has demonstrated the superiority to standard 
chemotherapy in patients with previously treated 
advanced NSCLC with ALK rearrangement [80]. A new 
inhibitor, LDK378, is in development, having received 
the FDA Breakthrough Therapy designation in March 
2013. This program, introduced in the summer of 2012, 
is intended to expedite the development and review of 
drugs that treat serious and life-threatening conditions 
and that have demonstrated substantial improvement over 
existing therapies on at least one clinically significant 
endpoint. This designation for LDK378 was based on 
phase 1 trial results data that showed marked responses 
in a majority of patients with ALK-positive NSCLC. An 
overall response rate of 80% was observed in the patients 
whose tumor progressed on crizotinib treatment. LDK378 
is currently being tested in a number of clinical trials, 
including NCT01685060, NCT01685138, NCT01283516, 
NCT01634763, NCT01828112, NCT01828099, and 
expanded treatment protocol trial NCT01947608 – 
both for patients previously treated with crizotinib 
and for treatment-naïve patients. Four more trials will 
start recruiting patients soon. There are several other 
ALK inhibitors currently evaluated in clinical trials, 
including X-396 that is being tested in the phase 1 trial 
NCT01625234. RO5424802/Alectinib is tested in phase 
1/2 trial (NCT01588028) for ALK rearranged tumors, and 
in a phase 2 trial NCT01801111 for patients who failed 
on crizotinib.  Preliminary results showing excellent 
activity were reported from a clinical trial in Japan [81], 
and RO5424802 received the Breakthrough Therapy 
designation in October 2013. AP26113, an ALK inhibitor 
from Ariad,  was  reported  to  show  efficacy  based  on 
preliminary results of trial NCT01449461. The drug was 
effective in patients previously treated with crizotinib, in 
patients with brain metastases and, interestingly, in EGFR-
mutant patients including T790M. 
HSP90 Inhibitors. 
The Hsp90 inhibitor ganetespib, in a preclinical 
study conducted in vitro and in animals, induced loss 
of EML4-ALK expression and depletion of multiple 
oncogenic signaling proteins in ALK-driven NSCLC 
cells [82]. Ganetispib had a greater in vitro potency and 
better  antitumor  efficacy  compared  to  crizotinib  [82]. 
Ganetespib (STA-9090) is being tested in clinical trials for 
ALK-positive lung cancer patients, alone (NCT01562015) 
or in combination with crizotinib (NCT01579994). A 
completed phase 2 trial of ganetespib showed clinical 
activity in heavily pretreated patients with advanced 
NSCLCs, particularly in patients with tumors positive 
for EML4-ALK [63]. In preclinical models, Ganetispib 
was shown to be not only effective in ALK positive 
adenocarcinoma, but was able to overcome resistance to 
crizotinib [82].  Another HSP90 inhibitor, AUY-922 is 
also in clinical trial for advanced ALK-positive patients 
(NCT01752400). NCT01772797 examines the safety 
of LDK378 in combination with AUY-922.  Phase I/II 
clinical trial NCT01712217 will explore HSP90 inhibitor 
AT13387 alone or in combination with crizotinib. 
Resistance to crizotinib
Patients treated with crizotinib usually develop 
resistance to it, and the mechanisms of this appear to 
be heterogeneous. Several patterns were described: 
secondary (gatekeeper) mutations in ALK that render 
the kinase resistant to crizotinib; increased ALK copy 
number, EGFR L858R mutation and high levels of 
amphiregulin in sera of resistant patients [83].  Another 
study of resistance to crizotinib also identified secondary 
mutations in ALK, in EGFR, and in KRAS [84].  Although 
crizotinib was ineffectual against EML4-ALK harboring 
the gatekeeper mutation, two structurally different ALK 
inhibitors, NVP-TAE684 and AP26113, were highly active 
against the resistant cancer cells in vitro and in vivo [85]. 
As mentioned above, RO5424802 is in clinical trial for 
patients who have failed crizotinib. A new ALK inhibitor 
in preclinical development, PF-06463922, showed activity 
in crizotinib-resistant tumors in mouse models, and was 
able to cross blood-brain barrier. It is about to enter 
clinical testing (NCT01970865).
MET
MET (mesenchymal-epithelial transition factor) 
RTK, also known as hepatocyte growth factor receptor 
HGFR, is a proto-oncogene with important implications 
in  NSCLC  [86].  MET  activation  induces  specific 
phosphorylation of several tyrosine residues, which, in 
turn, activates multiple downstream signaling pathways, Oncotarget 1401 www.impactjournals.com/oncotargetOncotarget 1402 www.impactjournals.com/oncotarget
including RAS/MAPK, PI3K, and SRC kinase pathways 
(reviewed in [87]). MET promotes epithelial-mesenchymal 
transition (EMT), at least in part through activation of 
SRC. Elevated levels of HGF and intratumoral MET 
expression have been associated with a more aggressive 
biology and a worse prognosis in NSCLC. Disregulation 
of MET pathway leads to cell proliferation, cell survival, 
angiogenesis, invasion, and metastasis. 
MET disregulation can occur through a variety of 
mechanisms including c-MET overexpression, activation, 
gene  amplification,  and  overexpression  of  the  c-MET 
ligand hepatocyte growth factor (HGF). Tests for the 
detection of these abnormalities are not FDA approved, 
nor is c-MET considered a predictive marker that informs 
clinical decision making.
MET mutations have been observed in about 5% of 
treatment-naive NSCLC [88], mainly within exons 2 and 
14, outside of the kinase domain. Mutations in MET are 
observed more often in smokers [89]. The MET mutation 
N375S was detected as a germline mutation in a high 
proportion of East Asian samples, and was correlated to 
incidence of squamous-cell carcinoma [89]. 
MET  amplification,  as  mentioned  above,  is  one 
of the mechanisms of the acquired resistance to EGFR 
inhibitors and occurs in about 20% of treated patients 
[90], but only in 1.4% of treatment-naïve patients [91], 
exclusively in AC. A splice mutation in MET deleting the 
juxtamembrane domain for binding the c-Cbl E3-ligase 
was observed in 3.3% of patients [91]; normally such 
binding leads to ubiquitination and receptor degradation, 
and loss of this domain leads to MET activation. 
MET overexpression has been observed in 25% 
to 61% of NSCLC patients [92, 93]. The MET ligand 
HGF is also expressed by tumor cells, with moderate 
overexpression observed in a high proportion of lung 
tumors [93, 94].
Potential therapeutic approaches for MET
MET inhibitors. Several targeted therapies for 
the treatment of aberrant MET activity are currently in 
clinical testing. MET inhibitor tivantinib (ARQ 197), in 
combination with erlotinib in previously treated patients, 
has shown better activity versus erlotinib alone in phase 
2 study [95]. Response rate was higher in KRAS-mutant 
NSCLC patients [95]. A randomized phase 3 study, 
NCT01395758, was completed, and did not meet its 
primary endpoint. However, further subset analysis is 
currently being carried out. Tivantinib might have an off-
target activity. 
Multi-RTK inhibitor Cabozantinib (XL184) is in 
active or planned trials for NSCLC, as a single therapy 
or with erlotinib (phase 2 trials NCT01866410 and 
NCT01708954 for previously treated NSCLC). Foretinib, 
a dual MET/VEGFR inhibitor, was in a dose escalation 
study in various solid tumors, but the best responses 
observed were stable disease [96]. Foretinib is tested 
alone or in combination with erlotinib in NCT01068587. 
Specific  MET  inhibitors  EMD  1214063  and  EMD 
1204831 are in safety testing in various solid tumors. 
Nonspecific inhibitor of MET MGCD265 is being tested 
in combination with either erlotinib or docetaxel in a phase 
1/2 trial NCT00975767 for NSCLC.
MET antibodies. A single-arm antibody directed 
against the extracellular domain of MET, called MetMAb 
(onartuzumab), has been tested in a randomized phase 
2 trial comparing its combination with erlotinib versus 
erlotinib alone as a second- or third-line treatment. 
Patients whose tumors had high c-MET expression had 
significantly  longer  PFS  with  MetMAb  plus  erlotinib 
compared with erlotinib monotherapy, and significantly 
longer OS (12.6 versus 4.6 months). In the cohort of 
patients who received MetMAb, median OS was much 
better for patients with high c-MET expression than for 
those negative for c-MET (12.6 versus 5.5 months) [97]. 
Several clinical trials are evaluating MetMAb in different 
settings of NSCLC, including a prospective, randomized 
phase 3 study designed to validate the MetMAb findings 
from the phase 2 study (NCT01456325), and a study in 
SQCC comparing chemotherapy combination alone to 
chemotherapy and MetMAb (NCT01519804).  
HGF antibodies. Two anti-HGF antibodies were 
tested in lung cancer patients. AMG-102 (rilotumumab) is 
a human monoclonal antibody that showed some activity 
in an early trial in patients with advanced solid tumors 
[98]. AMG-102 is currently being tested in combination 
with erlotinib (NCT01233687). A second HGF antibody 
AV-299 was tested in phase 1 trial without promising 
results. Based on this initial experience, there is currently 
limited interest in clinical development of anti-HGF drugs. 
ERBB2/HER2
HER2 is a member of the EGFR/ERBB family of 
RTKs, best known for its role in breast cancer, where 
it is targeted by the antibody trastuzumab.  HER2 is 
unique in the EGFR family because it does not bind 
any known ligands of the EGF family, but exists in an 
unliganded, active confirmation.  Its function is exerted via 
heterodimerization with other family members. Mutations 
in HER2 were identified in 2% to 4% of NSCLC examined 
[99-101].  Most mutations occur in exon 20 affecting the 
ATP-binding pocket.  A recent study has confirmed the 
previously reported higher rate of association of HER2 
mutations with lung cancer in women and nonsmokers 
[102]. Tumors with the HER2 mutation were mostly 
adenocarcinomas, with the-HER2 mutation almost always 
an exclusive driver [102].  Even though mutations are rare, 
HER2 more frequently shows a moderately increased 
copy number in AC, with different frequencies reported in 
different studies [103-105], and around 10% in the large 
NGS study [2]. Oncotarget 1403 www.impactjournals.com/oncotarget
Mutations aside, ERBB2 was implicated in 
resistance of NSCLC cell lines to EGFR-directed antibody 
cetuximab  in vitro. Activation of ERBB2 signaling 
in cell lines through ERBB2 amplification or through 
heregulin up-regulation resulted in persistent activation 
of extracellular signal-regulated kinase (ERK1/2) and 
cetuximab resistance [106].
Potential therapeutic approaches for HER2 
Thus far there has been limited clinical experience 
with HER2 inhibitors in treatment of NSCLC, but a 
number of trials are ongoing. Responses were observed 
with trastuzumab and afatinib [102, 107] but not with 
other EGFR-family-targeted drugs such as gefitinib or 
lapatinib [108, 109]. Neratinib is a second-generation, 
irreversible inhibitor of HER2 that is currently being 
tested in NSCLC (NCT01827267). A dose-finding study 
of neratinib combined with temsirolimus produced some 
clinical responses in HER2 mutant NSCLC patients 
[110]. MGHA22 is an anti-HER2 antibody with an 
improved characteristic in the Fc domain that enables 
enhanced binding of to the Fc-gamma receptor on 
NK and macrophages for antibody-directed cell lysis. 
MGHA22 is currently being trialed in NCT01148849 
and NCT01195935. Trial NCT01526473 is testing a new 
vaccine, HER2 VRP or AVX901, based on Venezuelan 
equine encephalitis virus. An attenuated strain of VEEV, 
in which 3 of the 7 viral genes were substituted with a 
truncated HER2 gene to create a self-amplifying replicon 
RNA, will be used to vaccinate patients with HER2-
expressing cancers. 
ERBB3
This RTK of the EGFR family might be involved 
in 2% of SQCC [4], though there is no direct evidence 
of functional significance of these mutations yet. ERBB3 
is unusual in that it lacks a kinase domain of its own, 
but it heterodimerizes with other members of the EGFR 
family, leading to potent activation of the PI3K pathway 
(Schoeberl et al., 2009) and providing a strong rationale 
for the inhibition of this RTK (reviewed in [111]). The 
rationale for clinical development of anti-ERBB3 drugs in 
combination with other EGFR family inhibitors is based 
on the ability of EGFR family members to heterodimerize 
with ERBB3, leading to activation of ligand-dependent 
signaling [58]. Dual inhibition of ERBB3 and EGFR 
shows synergistic effects in vitro in cell lines derived from 
pelural effusion of lung adenocarcinoma patients [112]. 
Interestingly, while ERBB3 supports PI3K signaling in 
epithelial cells, in vitro this leads to downregulation of 
Erbb3 and rewiring of PI3K activation [113]. 
Potential therapeutic approaches for HER3 
Clinical studies of anti-ERBB3 antibody MM-
121 are ongoing in NCT00994123 and NCT01451632, 
including combination study with erlotinib. NCT01451632 
examines effects of MM-121 with cetuximab (anti-EGFR 
antibody) and chemotherapeutic agent irinotecan. 
ROS1
ROS1 is a transmembrane proto-oncogene RTK of 
the insulin-receptor family that is aberrantly expressed 
in neoplasms of the central nervous system. ROS-1 
translocations are observed in glioblastoma and other 
tumors and, infrequently, in NSCLC, in about 1% to 2% of 
patients (reviewed in [114]). Patients with ROS1-mutant 
tumors are characteristically young nonsmokers. The 
fusions of ROS with SLC34A2 and CD74 were identified 
in a phosphoproteomic screen of tyrosine kinase activity in 
lung cancer [115], and have been observed predominantly 
in  AC  [116,  117].    ROS1  rearrangement  defines  a 
molecular subset of NSCLC with clinical characteristics 
that are similar to those observed in patients with ALK-
rearranged or EGFR-mutated NSCLC [117].  They are 
mutually exclusive with EGFR, KRAS, and EML4-ALK 
mutations.
Potential therapeutic approach for ROS1-positive 
NSCLC
ROS1-positive NSCLC represents a unique subset 
of patients for whom the c-MET/ALK inhibitor crizotinib 
has shown potential as a very effective therapeutic 
strategy. A phase 1 trial evaluating crizotinib in advanced 
solid tumors that possess the ROS1 translocation is 
currently ongoing (NCT00585195).  The investigational 
ALK inhibitor LDK378, fast-tracked by FDA, might 
also have an inhibitory effect on ROS1, though it is not 
presently  investigated  specifically  in  ROS1-positive 
patients. AP26113 is a dual EGFR/ALK inhibitor in 
clinical development (NCT01449461), and the ongoing 
trial will recruit patients with ROS1-positive NSCLC 
as well. ALK/ROS1 inhibitor PF-06463922 is in early 
phase  trial  NCT01970865.   An  efficacy  trial  of  HSP 
inhibitor AUY922 is recruiting patients with various RTK 
alterations including ROS1 fusion.  Trial NCT01712217, 
which explores crizotinib in combination with HSP90 
inhibitor AT13387, is recruiting patients with both ALK- 
and ROS1-positive NSCLC who have failed crizotinib. A 
new ALK/ROS inhibitor PF-06463922 showed activity in 
crizotinib-resistant tumors in mouse models and is about 
to enter clinical testing (NCT01970865). Resistance 
to crizotinib in a patient with CD74-ROS1 fusion was 
already reported, apparently as a consequence of a de novo Oncotarget 1404 www.impactjournals.com/oncotarget
mutation of G2032R in the ROS1-kinase domain [118]. 
Preclinical studies showed that ROS1-positive cancer 
cells, including the G2032R variant, are sensitive to MET/
VEGFR2 inhibitor foretinib, strongly suggesting that 
foretinib could be the drug of choice for ROS1-positive 
NSCLC [119].
RET
RET (rearranged during transfection) fusions 
are considered to be driver mutations in lung cancer 
because they are not found in association with changes 
in EGFR, KRAS, ALK or HER2. RET rearrangements 
are common (30%) in papillary thyroid carcinomas [120], 
and mutations are found in 50% of medullary thyroid 
carcinomas [121].  RET is an RTK involved in neural crest 
development. RET ligands belong to the glial cell-derived 
neurotrophic (GDNF) family, and upon engagement, RET 
induces activation of multiple signaling pathways: PI3K, 
MAPK, JNK, p38, SRC, ERK5, PLC-γ, and STAT [122]. 
The most common fusion partner of RET in NSCLC is 
KIF5B, a gene in the family of motor proteins, kinesins 
[117,  123,  124].  Other  partners  have  been  identified: 
CCDC6 [117] and NCOA4 [125]. Translocations are 
observed in a small percentage of patients (1% to 2%), 
but stratification by smoking and age results in a higher 
percentage of RET translocations. Patients with RET 
translocations tend to be younger nonsmokers and have 
poorly differentiated tumors [125].
Potential therapeutic approach for RET-positive 
adenocarcinoma
The multikinase inhibitor vandetanib (ZD6474) is 
an inhibitor of RET and VEGFR1, and is approved for 
medullary thyroid cancer with RET fusions. Its activity 
in lung adenocarcinoma with translocated RET is 
currently undefined. None of the trials conducted thus 
far included sequencing to determine the status of RET, 
but one ongoing trial of vandetanib, NCT01823068 (in 
South Korea), will recruit patients whose tumors harbor 
a RET translocation. Vandetanib is also being tested 
in combination with the MEK inhibitor selumetinib 
NCT01586624.    Significant  increases  in  PFS  were 
reported in three out of three patients with RET-
rearranged AC in a small trial of cabozantinib [126]. 
Other multikinase RTK inhibitors are also being tested 
in RET-positive AC, including cabozantinib (XL-184) in 
NCT01639508, ponatinib in NCT01813734, and sunitinib 
in NCT01829217. 
FGFR1
FGFR (fibroblast growth factor receptor) pathway 
signaling normally contributes to the physiologic 
processes of tissue repair, hematopoiesis, angiogenesis, 
and  embryonic  development.  Focal  amplification  of 
FGFR1 was detected in 21% to 22% of SQCC tumors 
according to two reports [127, 128], but is quite rare in 
AC (1% to 3%) [2, 128].  Other members of the family 
(FGFR2 and FGFR3) might be also activated in SQCC 
at low frequencies of 2% to 3% [4]; mutations in these 
receptors are oncogenic in vitro and in vivo, and are 
sensitive to RTK inhibitor pazopanib [129]. FGFR1 is 
the only RTK amplified at appreciable frequency (6%) in 
SCLC [5].  
SQCC tumors with amplified FGFR1 were found to 
have high expression of MYC in 40% of cases, and this 
subset is more sensitive to inhibition of FGFR, providing 
a potential response-predictive biomarker [130]. 
Potential therapeutic options to FGFR alterations
FGFR inhibitors PD173074 and AZD4547 inhibit 
proliferation of SQCC in vitro and tumor growth in vivo 
[128,  131].   AZD4547  is  under  clinical  investigation 
in SQCC, including a phase 2 trial NCT01795768 
in molecularly selected patients, a phase 1 trial 
NCT00979134, and a phase 1/2 trial with docetaxel 
for recurrent NSCLC and SQCC (NCT01824901). 
BGJ 398 is a pan-FGFR inhibitor being investigated 
in a dose-escalation (safety) trial (NCT01004224) for 
FGFR-amplified  malignancies.  The  multi-RTK  and 
SRC-family inhibitor BIBF 1120 (vargatef) is currently 
being explored in Korean patients with small cell lung 
cancer (SCLC) in NCT01441297. Dovitinib (TKI258) 
is an inhibitor of FGFR3 and potentially other FGFRs, 
which is currently being tested in patients with advanced 
NSCLC or colorectal cancer (NCT01676714) and in 
patients with SQCC (NCT01861197) and various tumors 
phase 2 NCT01831726). Nintedanib is entering phase 
2  studies  in  patients  with  FGFR1  amplified  NSCLC 
(NCT01948141).  BAY1163877, a pan-FGFR inhibitor, is 
entering a safety study in patients with FGFR-amplified 
cancers (NCT01976741). GSK3052230, an antagonist 
of FGFR receptors, is a fusion protein composed of the 
extracellular domain of FGFR1 and the Fc portion of 
IgG1. It is currently in a phase 1 study NCT01868022 as 
a monotherapy or in combination with chemotherapy in 
SQCC patients with alterations in FGF receptors.
DDR2
Discoidin domain receptors (DDRs) are RTKs 
that belong to the same family as EGFR. However, Oncotarget 1405 www.impactjournals.com/oncotarget
DDRs are unique because they have native collagens 
as their ligands. DDR2 mutations, identified by Sanger 
sequencing as the tyrosine kinome in 11 of 290 (3.8%) 
SQCC samples, may alter kinase activity, ligand binding, 
or DDR2 localization [132]. A squamous cell lung cancer 
patient with a response to dasatinib and erlotinib treatment 
harbored a DDR2 kinase domain mutation [132]. A phase 
2 trial NCT01514864 is currently examining dasatinib in 
NSCLC with DDR2 mutation. However, previous studies 
of dasatinib in unselected patient populations showed 
significant toxicity and lack of benefit [133].
IGF1R 
Insulin growth factor 1 receptor is an abundantly 
expressed RTK, frequently elevated in lung cancer, 
particularly in SCLC and certain NSCLC patients.  There 
has been interest in developing IGF1R-targeting clinical 
options,  but  the  validation  of  the  efficacy  of  IGF1R-
targeted agents in large clinical trials had largely failed.   
Considering the scarcity of targeted agents for SCLC, 
IGF1R is certainly an attractive target.  IGF1R activates 
PI3K and MAPK signaling, and recently it was shown that 
IGF1R is involved in signaling from mutant KRAS, which 
also makes it a very attractive target in KRAS-mutated 
NSCLC.  NSCLC lines with activated KRAS depend on 
the basal IGF1R activity for activation of PI3K pathway 
[134]. Inhibitors of IGF1R are active in cell lines with 
mutant, but not wild type, KRAS. Moreover, inhibition of 
both IGF1R and MEK in vitro and in vivo in NSCLC with 
mutant KRAS is highly cytotoxic [134].
Potential therapeutic options for activation of 
IGFR1
Anti-IGF1R antibody figitumumab (CP-751,871) 
in combination with carboplatinum-paclitaxel was tested 
in NSCLC with some initial promising results [135], but 
subsequent trials were discontinued because of futility and 
unacceptable toxicity. Another antibody, cixutumumab, 
was in clinical testing combined with chemotherapy, 
but its development was discontinued based on negative 
results of a randomized phase 2 trial. The monoclonal 
antibody AMG-479 (ganitumab) was tested in several 
clinical trials, which were either terminated or did not 
meet endpoints, with only one trial, NCT01327612, still 
ongoing. The combination of erlotinib with the IGF1R 
monoclonal antibody, R1507, did not reveal a statistically 
significant improvement in PFS or OS in NSCLC [136].   
AXL1717, or picropodophyllin, is a small-molecule 
inhibitor of IGF1R, which is currently tested in patients 
with SQCC in trial NCT01561456.  OSI-906/linsitinib 
is another small-molecule. dual-kinase inhibitor of both 
IGF1R and the insulin receptor. OSI-906 is in randomized 
trials for SCLC (NCT01533181, NCT01387386) and 
NSCLC (NCT01221077, NCT01186861).
NTRK1
About 3% of NSCLC tumors that have no known 
driver mutation were found to harbor oncogenic fusions 
of nerve growth factor receptor NTRK1 with MPRIP or 
CD74 [137]. Translocations were found in women never-
smokers. NTRK1 encodes protein TRKA with tyrosine 
kinase activity.  Lung cancer cells with NTRK1 fusions 
were sensitive to kinase inhibitors of TRKA, and one of 
them showed modest activity in a patient with NRFK1 
translocation [137]. Crizotinib has been shown to have 
modest activity against tumors that have NTRK1 fusion. 
1.2. RAS PATHWAY
KRAS
KRAS belongs to a family of small GTPases 
(proteins with intrinsic GTPase activity) that regulate 
cellular behavior in response to extracellular stimuli. Ras-
regulated signal pathways control processes such as actin 
cytoskeletal integrity, proliferation, differentiation, cell 
adhesion, apoptosis, and cell migration via the MAPK and 
PI3K pathways. KRAS mutations are observed in close to 
30% of adenocarcinomas of the lung, but are uncommon 
in SQCC (about 5%) [138]. KRAS mutations are found 
in majority of mucinous adenocarcinomas [139, 140].   
Point mutations at codons 12, 13, or 61 in the KRAS 
oncogene lead to constitutive activation of KRAS protein 
via changes at the GTP binding domain, which prevents 
the conversion of GTP to GDP. KRAS mutations are seen 
more frequently in smokers (26%) versus never-smokers 
(6%) [141].  In clinical trials, the prognostic significance 
of KRAS mutations in NSCLC has been variable, with 
some trials and pooled analyses reporting worse overall 
prognosis and others failing to identify any difference in 
survival outcomes [142, 143]. The presence of a KRAS 
mutation has not consistently resulted in different survival 
outcomes [141, 144].
Despite widespread KRAS mutations in a variety 
of cancers, this protein has not been successfully targeted 
therapeutically; however, several approaches are being 
tested in clinical trials. KRAS-mutant tumors might be 
uniquely sensitive to combinations of IGF1R and MEK 
inhibitors [134]. KRAS-driven lung tumors are dependent 
on the activity of the PI3K pathway, as shown recently in 
a mouse model. KRAS interacts with the p110a subunit of 
PI3 kinase, and disruption of this association impedes both 
development and growth of already established tumors – 
in particular, in combination with MEK inhibition [145]. 
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identified BCL-XL and MEK inhibition as a potentially 
successful strategy for treatment of KRAS-mutant 
adenocarcinoma [146].  There is potential in targeting the 
membrane localization of KRAS, which is essential for 
its activity.  The correct localization of prenylated KRAS 
depends on its interaction with prenyl-binding protein 
PDEα. A compound was identified in a large screen and 
further optimized to disrupt the interaction of PDEα with 
KRAS.  This compound, deltarasin, inhibited growth of 
KRAS-mutant pancreatic cells in vitro and in vivo, and 
might be promising for the future drug discovery efforts 
[147].
Another cellular module activated by KRAS is 
IKK-related  kinases  TBK  and  IKKα,  which  promote 
KRAS driven tumorigenesis by upregulating production of 
cytokines CCL5 and IL6. Compound CYT387 previously 
known as inhibitor of JAK, is also a potent inhibitor of 
TBK/IKKα  with  anti-tumor  activity  in  mouse  models 
[148].
Lastly, the “untargetability” of KRAS has been 
challenged recently, with development of specific small-
molecule inhibitors against KRAS (G12C) that have 
undergone preclinical testing, and hopefully will come to 
clinical fruition [149].
Potential therapeutic approach for KRAS 
mutated NSCLC
MEK and mTOR inhibitors. Preliminary evidence 
suggests that MEK inhibition may be an effective strategy 
in treating KRAS-mutated tumors and a number of 
clinical trials are currently studying this approach. The 
MEK inhibitor selumetinib showed promising results in 
KRAS-mutated NSCLC when combined with docetaxel in 
a phase 2 clinical trial [150].  The combination treatment 
was associated with improved PFS and a trend to longer 
OS.  Another MEK inhibitor, trametinib, is currently 
trialed in combination with several chemotherapeutic 
drugs or erlotinib (NCT01192165).  A recent study 
identified the basis of different activity of MEK inhibitors 
in BRAF versus KRAS mutant cancers. Unlike trametinib-
like inhibitors, which inhibit phosphorylated MEK and 
are effective in the setting of BRAFV600 mutants, the 
new class of inhibitors, like GDC-0623, inhibit feedback 
activation of MEK by RAF, and are therefore more 
efficacious in the setting of mutant KRAS [151]. GDC-
0623 is currently in a phase 1 clinical trial NCT01106599.
The combination of erlotinib and tivantinib (MET 
inhibitor) in NSCLC showed clinical activity in patients 
with KRAS-mutated cancers, even though the endpoints 
of the trial were not achieved [95]. Tivantinib with 
erlotinib is currently being tested versus chemotherapy 
in NCT01395758. Lastly, the combination of inhibitors 
targeting both MAPK and AKT/PI3K pathways are 
currently being tested in early-phase trials NCT01363232 
(MEK162 and BKM120) and NCT01449058 (MEK162 
and BYL719).
HSP90 inhibitors. Another approach to targeting 
KRAS-mutated tumors clinically involves inhibition of 
the molecular chaperone Hsp90. Retaspimycin HCL is 
currently being tested with docetaxel (NCT01362400), and 
everolimus (mTOR inhibitor) in NCT01427946; however, 
preliminary reports on the docetaxel combination are 
disappointing. The already-mentioned inhibitor AUY922 
is currently being examined in a single-arm study in 
NSCLS patients with KRAS, EGFR mutations, and EML-
ALK translocation (NCT01124864).
REOLYSIN is a proprietary formulation of human 
reovirus, a naturally occurring oncolytic virus that 
preferentially replicates in cancer cells with activated 
KRAS. Reolysin in combination with carboplatinum and 
paclitaxel has been evaluated in several solid tumors. 
REOLYSIN and chemotherapy are currently in several 
phase 2 clinical trials including NSCLC with mutant 
KRAS or activated EGFR (NCT00861627), SQCC 
(NCT00998192), and as salvage therapy in previously 
treated NSCLC (NCT01708993). Preliminary positive 
results were reported by the manufacturer in September 
2013, with an overall response rate of 92% in a trial 
involving 25 patients with SQCC.
The proteasome inhibitor bortezomib is being tested 
in KRAS-mutant NSCLC phase 2 trial NCT01833143. 
NF1/neurofibromin
NF1 is negative regulator of RAS pathway 
activation, and a tumor suppressor. Germline mutations in 
NF1 deregulate both PI3K and MAPK pathways and result 
in familial neurofibromatosis. Mutations of NF1 in AC 
were discovered through sequencing of a larger number 
(623) of “suspected” cancer-related genes in a large 
number (188)  of tumors [88]. NF1 is mutated in more 
than 10% of AC, but is also disrupted in 11% of SQCC 
[4]. The functional significance of NF1 in lung cancer has 
not been established, but because of its well-known role 
in many other cancers it is reasonable to assume that it’s a 
driver event in lung cancer as well. There are no specific 
treatment options for NF1- disrupted tumors, but in recent 
studies of NF1 in melanoma, it was successfully targeted 
in mouse models with a combination of MEK and PI3K/
mTOR inhibitors [152]. A trial of MEK inhibitor MEK162 
NCT01885195 is recruiting patients whose tumors 
have alterations in components of the RAS-RAF-MEK 
pathway, including NF1. Oncotarget 1407 www.impactjournals.com/oncotarget
NRAS, HRAS
Mutations in these well known oncogenic members 
of RAS family are relatively rare in AC and SQCC (<1%), 
except HRAS in SQCC (3%; [4]). In a very large cohort 
of lung tumors, NRAS mutations were present in 0.7% 
and most NRAS-mutated tumors were AC; these had 
no other driver mutations implicating NRAS in driving 
tumorigenesis [153]. Five of six cell lines established 
from NRAS-mutant AC were sensitive to MEK inhibitors 
selumetinib and trametinib, but not to other inhibitors 
tested [153].
RASA1
RASA1 (p120Ras GAP) is a well-known GTPase-
activating protein (GAP) that functions as a negative 
regulator of Ras signaling downstream of several 
growth-factor receptors [154]. RASA1 mutations have 
been reported to be associated with hereditary capillary 
malformations, but their potential involvement in cancer 
only came to light through NGS-based analysis of SQCC, 
where its recurrent mutations were found in 4% of tumors 
[4]. The functional significance of this remains unknown.
1.3. BRAF/MAPK PATWHAY
BRAF
BRAF is a serine-threonine kinase whose only 
known substrates are MEK1 and MEK2 in the MAPK 
pathway. Mutated, activated BRAF occurs in about 7% of 
all human cancers, but about 50% of melanomas contain 
BRAF mutation at V600.  NSCLC tumors harbor BRAF 
mutations infrequently, including D594G and L596R 
mutation in the kinase domain [155], and G465V or 
G468A mutations in the G-loop of the activation domain 
[156]. Only about half of BRAF mutations in NSCLC are 
V600E [157].  The frequency of BRAF mutations in AC 
is ~6%, and in SQCC ~4%.  BRAF mutations occur much 
more commonly in smokers than in nonsmokers [156].
Similarly to melanoma, BRAF mutations on their 
own induce a senescent phenotype, which manifests 
as benign adenomas in a mouse model of lung 
carcinogenesis.  Single-copy loss of LKB1 (see below) 
is sufficient to drive the malignant progression of these 
tumors to carcinomas [158]. BRAFV600E-driven lung 
tumors in a mouse model depend on autophagy to sustain 
their glutamine metabolism and growth, indicating that 
targeting autophagy in this context could be clinically 
relevant [159].
Potential therapeutic approach for BRAF-
mutated NSCLC
The BRAF inhibitor vemurafenib, approved for 
melanoma, is of limited use in NSCLC with BRAF 
mutations other than V600E, but might be of value in 
tumors with V600E mutations. Other BRAF mutations 
could be potentially targeted with MEK inhibitors. The 
RAF inhibitor sorafenib was tested in an unselected 
population with NSCLC, and had little if any effect. 
However, some clinical trials are addressing the efficacy 
of targeted drugs in biomarker-selected patients. Trial 
NCT01336634 examines BRAF inhibitor dabrafenib/
GSK2118436 in BRAF-mutant NSCLC, and preliminary 
results suggest a promising clinical activity in pretreated 
patients with stage IV NSCLC carrying BRAFV600E 
mutation (overall response rate of 60%, BRF113928).   
MEK  inhibitor  selumetinib/AZD6244  is  tested  in 
various-BRAF mutant malignancies including NSCLC 
in NCT00888134. BRAF mutant tumors are also targeted 
using the combination of inhibitors of both MAPK and 
AKT/PI3K pathways in early-phase trials NCT01363232 
(MEK162 and BKM120) and NCT01449058 (MEK162 
and BYL719).
Resistance to BRAFV600E inhibition in NSCLC 
involves some of the mechanisms previously encountered 
in BRAF mutant melanoma.  One identified mechanism 
involves expression of an aberrant form of BRAFV600E 
resistant to inhibition, and the other relies on the autocrine 
EGFR signaling driven by c-Jun–mediated EGFR ligand 
expression and leading to activation of AKT [160]. 
1.4. PI3K PATHWAY
The phosphatidylinositol 3-kinase (PI3K)/
Akt pathway is activated in many different cancers, 
including  NSCLC.  PIK3CA  is  the  class  IA  PI3Kα 
catalytic subunit p110α. Upon growth factor stimulation, 
PIK3CA is activated, increasing PIP3 levels which drives 
phosphorylation of AKT and downstream processes such 
as higher protein translation (through mTOR activation), 
cell division, and induction of anti-apoptotic response. 
Activating mutations in PIK3CA have been implicated in 
various cancers, and occur predominantly in the helical 
or kinase domains of the alpha p110 catalytic subunit. 
PI3K pathways activity is downregulated by the tumor 
suppressor PTEN, a phosphatase subject to deletions or 
mutations in a wide variety of tumors. 
PIK3 kinase
All available data show that direct alterations in this 
pathway are much more frequent in SQCC versus AC, 
with mutations in three genes – PIK3CA, PTEN, and AKT Oncotarget 1408 www.impactjournals.com/oncotarget
significantly enriched in SQCC (Table 2). In addition, 
PIK3CA gene amplification might occur in SQCC at a 
much higher frequency than do activating mutations. 
According to one study, PIK3CA copy-number gain was 
found in ~33% of squamous cell tumors and in ~6.2% 
of adenocarcinomas [161]. Large-scale NGS analysis of 
SQCC found PIK3CA mutations in 16% of SQCC [4] 
versus previously reported 3.6% of SQCC and 2.6% of 
AC [161], with exon 9 as the most frequently mutated 
site. PIK3CA mutations are not mutually exclusive with 
EGFR or KRAS mutations, but are mutually exclusive 
with FGFR amplification in SQCC [4]. 
Increase in PI3Kβ expression and loss of PTEN 
is also observed more often in SQCC compared to AC, 
suggesting that targeting of PI3K is a justified strategy in 
treatment of SQCC [162].
PTEN
Inactivating mutations or deletions of PTEN, a lipid 
phosphatase that dephosphorylates PIP3 and negatively 
regulates AKT, are observed in a wide variety of cancers, 
including lung cancer.  PTEN mutations (in exons 5–8) 
were observed in 4.5% of NSCLC, significantly more 
frequently in SQCC (10% [163] and 8% [4]).  Copy-
number losses of PTEN are not often associated with 
NSCLC. However, loss of PTEN protein is observed much 
more frequently, through loss of copies or methylation – in 
particular, in SQCC [164]. A recent study has found that a 
low level of PTEN expression does not necessarily signify 
high activity of AKT, and that areas with different levels of 
AKT activation co-exist within the same adenocarcinoma 
of lung [165]. Apparently, signaling from IGF1R and other 
factors influence activity of AKT in PTEN-low cells. 
AKT
Mutations of AKT1, a central kinase in the PI3K 
pathway, are rare in NSCLC, occurring in ~1.9% of 
cases, but are more frequent in SQCC (5.5%)[166].  The 
large-scale NGS analysis of SQCC identified even more 
frequent activating mutations in AKT3 – in 16% of tumors 
[4] – further underlining the significance of the PI3K/AKT 
pathway in pathogenesis of SQCC.  
Potential therapeutic approaches for alterations 
in PI3K-AKT pathway
There are at least three potential targets for 
therapeutic intervention in this pathway: AKT, PI3K, and 
mTOR. Several drugs are in clinical development against 
all three targets, including mTOR inhibitors that are 
approved for other cancer types.
PI3K inhibitors. Several phase 1 and 2 trials are 
currently ongoing, targeting PI3K in NSCLC either alone 
or in combination with standard, cytotoxic chemotherapy. 
These agents include PX-866, a PI3K inhibitor tested 
with docetaxel in a phase 1/2 trial with a placebo arm 
(NCT01204099). A phase 1 trial of the PI3K inhibitor 
BKM120 in combination with chemotherapy is planned 
(NCT01723800), and a phase 2 single-agent trial is 
ongoing  (NCT01297491). Trial NCT01487265 will 
explore the combination of BKM-120 and erlotinib in 
patients that previously responded to erlotinib but relapsed.   
PI3K inhibitor GDC-0941 is also in phase 2 combination 
trials (NCT01493843, NCT00974584). NCT00975182 is a 
phase 1 trial exploring the combination of GDC-0941 with 
erlotinib.  Another PI3K inhibitor, SAR245408, has shown 
promising clinical activity in NSCLC [167].
AKT inhibitors. Phase 1 and 2 trials are currently 
recruiting that offer MK2206 – an oral, potent, allosteric 
inhibitor of AKT – in combination with either erlotinib or 
gefitinib in advanced NSCLC. NCT01294306 is a phase 2 
trial that examines combination of erlotinib and MK2206; 
NCT01147211  explores  gefitinib  with  MK2206.  NCI 
is sponsoring trial NCT01306045 involving molecular 
profiling followed by administration of relevant targeted 
therapies, among them MK2206 for mutations in PI3K, 
AKT, or PTEN.  
mTOR inhibitors. Multiple phase 1 and 2 trials 
are recruiting patients for treatment of advanced NSCLC 
with mTOR inhibition either alone or in combination with 
chemotherapy or radiation therapy. These include agents 
such as everolimus (>30 trials), sirolimus (>30 trials), and 
temsirolimus (almost 30 trials).
1.5. LKB1 (STK11)/AMPK PATHWAY
LKB1
LKB1 is a known tumor suppressor whose germline 
mutations are responsible for the familial cancer syndrome 
known as Peutz-Jeghers, characterized by increased risk 
for epithelial cancers including lung carcinomas. LKB1 is 
an AMPK-activating kinase, and as such controls AMPK 
function as energy sensor and master regulator of cellular 
growth and metabolism. AMPK regulates activity of 
mTORC by phosphorylating TSC1 in one of the AMPK-
governed pathways, which also include regulation of 
OXPHOS and autophagy.
LKB1 mutations are found in 15% to 30% of 
NSCLC, and half of these tumors have concurrent 
mutations in KRAS [168].  Another study found 
inactivation of LKB1 in 34% and 19% of 144 human 
lungs in AC and SQCC, respectively [169]. Inactivation of 
LKB1 on the background of oncogenic KRASG12D in a 
mouse model resulted in lung tumors with high penetrance 
for metastases [169]. Expression profiling of these tumors Oncotarget 1409 www.impactjournals.com/oncotarget
and human lung cancer cell lines identified a variety of 
metastases-related genes (NEDD9, VEGFC, CD24) as 
targets of LKB1. Integrated analysis of transcriptome and 
phosphoproteome identified the SRC kinase activation as 
a frequent event in tumors with LKB1 mutations [170]. 
Mutant LKB1 confers a major metabolic deficiency 
on tumors driven by Kras in genetically engineered mouse 
models. Dtymk, encoding deoxythymidylate kinase, which 
catalyzes dTTP biosynthesis, is synthetically lethal with 
Lkb1 deficiency in mouse and human lung cancer lines. 
Global  metabolite  profiling  demonstrated  that  Lkb1-
null cells had striking decreases in multiple nucleotide 
metabolites as compared to Lkb1-wt cells. DTYMK is 
therefore a potential therapeutic target in NSCLC [171]. 
Adenocarcinoma cells with mutant KRAS and 
loss of LKB1 are also addicted to the mitochondrial 
metabolism driven by lysosomal degradation of 
macromolecules which, in turn, depends on coatomer 
complex 1 (COP-1) [172].
Potential treatment options for LKB1-deficient 
cancers 
In a mouse model mentioned above, triple inhibition 
of SRC, MEK1, and PI3K resulted in tumor regression 
[170]. Biguanide compounds traditionally used for 
treatment of diabetes have shown activity in pre-clinical 
models of NSCLC with LKB1 and KRAS mutations [173]. 
In this study, metformin, in wide use for diabetes, was less 
potent than phenformin, which fell out of favor because 
of its tendency to induce lactic acidosis in some patients. 
Neither is likely to be effective as single treatments for 
NSCLC with LKB1 mutations. Metformin is currently 
being tested in combination with Paclitaxel, Carboplatin, 
and Bevacizumab in a phase 2 randomized clinical trial 
NCT01578551 for adenocarcinoma of lung. 
1.6. TP53 PATHWAY
TP53
Inactivating mutations in TP53 are the most 
common alterations affecting any specific gene in human 
cancer.  Inactivating mutations in TP53 disrupt its key 
function in controlling cellular proliferation and apoptosis. 
Some mutations in TP53 confer “gain of function”, and 
the resulting mutant TP53 protein actually contributes to 
different stages of tumorigenesis or to the drug resistance. 
Mutations in TP53 in lung cancer are strongly associated 
with smoking, and are also the most common somatogenic 
alterations in NSCLC, occurring in over half of AC, 80% 
of SQCC and 70% of SCLC. The TP53 locus is also 
frequently affected by copy losses. Mutations in TP53 
are associated with poor prognosis [174] and resistance 
to chemotherapy.
MDM2
E3 ubiquitin ligase MDM2 binds to TP53 and 
promotes degradation of p53 through ubiquitin-proteasome 
pathway. MDM2 is amplified in 22% of NSCLC patients 
with and is associated with poor OS [175].  Prevention of 
MDM2 binding could restore TP53 function in wild-type 
TP53 tumors.
The MDM2-TP53 interaction has attracted serious 
efforts  to  develop  specific  inhibitors.  Discovery  of 
Nutlin-3, a promising inhibitor of MDM2 binding [176] 
energized the search for clinically active drugs. Early 
clinical testing of one such inhibitor, JNJ-26854165, did 
not provide a basis for continuation. The new generations 
of Nutlin-based and other drugs are in clinical studies for 
various solid tumors. Encouraging results were reported 
for one of them, R7112/RO5045337, in early clinical 
testing for liposarcoma and other tumors [177]. Other 
drugs – SAR405838 and RO5503781, also small-molecule 
inhibitors of the MDM2-TP53 interaction – are in clinical 
development for cancers other than lung. APR-246 
(PRIMA-1MET), a drug that restores activity of unfolded 
or mutant p53, was safe and showed indications of clinical 




RB1 is a well-known tumor suppressor with 
an important role in controlling the cell cycle, that 
is frequently inactivated in many human cancers. 
Hypophosphorylated RB controls the transcription factors 
E2F1, E2F2, and E2F3, which are necessary for the G1 
to S transition of the cell cycle. In normal cells, RB1 is 
phosphorylated by the cyclin D/CDK4 complex to release 
E2F factors for initiation of the cell cycle. Mutations 
of RB1 are rare in AC, more frequent in SQCC (7%), 
and ubiquitous in SCLC at over 90% of tumors [179].   
Nevertheless, frequent disruption of the CDKNA2 locus 
in SQCC significantly increases the involvement of RB1-
mediated pathways in this type of lung cancer. 
CDKNA2 locus 
Two tumor suppressors are encoded within this 
CDKNA2 locus: p14ARF, which activates p53 through 
inhibition of its major negative regulator MDM2; and 
p16INK4a, a cyclin-dependent kinase inhibitor that Oncotarget 1410 www.impactjournals.com/oncotarget
activates retinoblastoma (RB) through negative regulation 
of CDK4. Loss of CDKN2A was reported to occur in 15% 
of SQCC and in >20% of adenocarcinoma.  P16INK4a 
is made nonfunctional by other types of alterations in 
SQCC, such as epigenetic silencing, exon skipping, and 
mutations, bringing the percentage of SQCC tumors with 
dysfunctional p16INK4a to 72% [4].
Potential therapeutic approaches to alterations in 
RB pathway
Potential  treatment  of  p16INK4A  deficiency 
could involve inhibition of CDK4/6. A trial of the 
CDK4/6 inhibitor PD0332991 in selected patients with 
advanced NSCLC and disrupted p16INK4a is ongoing 
(NCT01291017). BAY1000394, a pan-CDK inhibitor, 
is currently being tested in a phase 1/2 trial in SCLC 
(NCT01573338), in combination with chemotherapeutic 
drugs (no placebo arm).
1.8. MYC PATHWAY
MYC family
The protoocogene and master regulator of 
transcription, MYC, controls transcription networks 
governing proliferation, metabolism, ribosome biogenesis, 
and protein synthesis. However, when overexpressed, 
MYC induces expression of pro-apoptotic protein BAX, 
which induces mitochondrially mediated apoptosis. MYC 
is amplified in >30% of adenocarcinomas and in 16% 
to 30% of SCLC patients. MYC-family genes such as 
MYC, MYCL1, and MYCN are amplified in a mutually 
exclusive manner in SCLC, as observed in other tumors 
of neuroendocrine origin. 
Experiments in a mouse model demonstrated that 
MYC is a valid therapeutic target in KRAS-driven NSCLC 
whose systemic inhibition eradicates tumors [180].   
However,  MYC  is  a  notoriously  difficult  therapeutic 
target, both because of its dominant role in many normal 
cellular processes, and because the tertiary structure 
of MYC protein is challenging in respect to modeling 
of inhibitors.  Nevertheless, the possibility of targeting 
downstream effectors of MYC remains viable. Thus, 
SCLC with MYC amplification is sensitive to inhibition 
of aurora kinase B (AURKB) [181].
The anti-apoptotic protein MCL1 is overexpressed 
and amplified in over 30% of AC [2, 182]. Examination 
of MCL1 in NSCLC patients showed no prognostic value 
[183]. However, subsequently MCL1 was identified as a 
protein whose expression is involved in survival of tumors 
that have high levels of the oncogene MYC. The majority 
of MYC- overexpressing NSCLC were positive for 
expression of MCL1, and together expression of these two 
genes significantly correlated with poor prognosis [184]. 
MCL1 is a member of the BCL2 family of anti-apoptotic 
proteins; inhibitors of this family have already been tested 
in men, and are still in clinical trials.
Transcriptional activity of MYC might be one of the 
converging factors of the activation of MAPK and PI3K 
pathways, and it could be targeted at the level of MYC 
accessory transcription factors such as bromodomain-
containing proteins [185]. A BET bromodomain inhibitor, 
JQ1, showed remarkable antitumor activity in a mouse 
model of KRAS-driven NSCLC, albeit sensitivity was 
abrogated in tumors containing both KRAS mutation and 
inactivation of LKB1 [186]. Downregulation of MYC 
protein was key to tumor response to JQ1 treatment.   
SCLC  cell  line  tumors  without  amplified  MYC 
genes show recurrent inactivation of MAX, a MYC-
associated protein. MAX mediates transactivation of 
pro-differentiation genes by virtue of suppressing activity 
of MYC, and it suppresses MYC-mediated activation of 
stemness-related genes [187], acting as a bona-fide tumor 
suppressor.
Potential therapeutic approaches for MYC 
overexpression
The aurora A kinase inhibitor MLN8237/alisertib 
is in clinical trial phase 1/2 for lung and other cancers 
(NCT01045421) and, in combination with erlotinib, for 
NSCLC (NCT01471964). Other aurora kinase inhibitors 
have been clinically tested in a variety of malignancies, 
but most showed little promise in terms of safety and/or 
efficacy.
1.9. EPIGENETIC PATHWAYS
Deregulation of the epigenome is now recognized to 
be a common feature of cancers. Epigenetics encompasses 
several processes, such as DNA methylation, histone 
modifications and RNA interference. The importance of 
DNA methylation, for example, was recognized when 
a study demonstrated clinical utility for prognostic 
purposes of the methylation status of a four-gene panel 
in early-stage NSCLC [188]. Since then, and largely 
due to unbiased NGS efforts, somatic alterations were 
identified in a number of genes involved in epigenetic 
regulation in all major types of lung cancer (Tables 
1 and 2). Interestingly, there is no overlap between the 
genes involved in regulation of epigenome between 
three major types of lung cancer.  This suggests different 
clinicopathological origins of the three major lung cancer 
types. 
In AC, mutations were found in tumor suppressors 
SMARCA4/BRG1 (SWI/SNF-related, matrix-associated, 
actin-dependent regulators of chromatin) and ARID1A Oncotarget 1411 www.impactjournals.com/oncotarget
(AT-rich interaction domain 1A) – both members of 
the SWI/SNF complex, in 8% and 10% of tumors, 
respectively [2]. BRG1 is inactivated in lung cancer in 
a manner mutually exclusive with MYC amplification 
[189] and inactivation of both BRG1 and MAX is a 
synthetic lethal interaction [187]. SWI/SNF-chromatin-
remodeling complex might protect cells against DNA 
damage by ensuring DNA repair through cell cycle arrest 
and apoptosis. A number of cancer-related proteins such 
as p21CIP, BRCA1, MYC, FOS, and LKB1 are known to 
associate with the SWI/SNF complex. 
SETD2 is a trimethyltransferase responsible for 
methylation of histone H3 on Lys36 (H3K36me3). This 
epigenomic histone mark ensures efficient DNA mismatch 
repair during replication process [190]. It is mutated in 4% 
to 5% of AC.
MLL2 is a histone methyltransferase mutated in 
19% of SQCC [4]. So far, this is the only gene product 
involved in epigenetic regulation that was found to be 
mutated in SQCC. MLL genes are also mutated in 10% 
of SCLC [5].
CREBBP/CBP and EP300, histone 
acetyltransferase coactivators, are mutated in 18% of 
SCLC [5]. Both are transcriptional coactivators with roles 
in many transcriptional programs and biological processes, 
conducted through acetylation of lysine residues on 
histones. 
EZH2 (enhancer of zeste homolog 2) is a 
methyltransferase and a component of repressive-PRC2 
complex that triggers transcriptional repression by 
catalyzing the addition of methyl groups onto lysine 27 of 
histone H3 (H3K27me2/3). EZH2 expression is controlled 
by E2F transcription factor that are, in turn, controlled by 
RB1, whose loss of function is a hallmark of SCLC. EZH2 
is an accepted oncogene in metastatic prostate cancer, and 
its expression is highly elevated in SCLC [6] where it is 
likely to activate a transcriptional program promoting the 
aggressive character of SCLC.  Higher EZH2 expression 
in lung AC is associated with shortened recurrence-free 
survival and overall survival [191].
KDM2A, histone H3 lysine 36 demethylase, is 
overexpressed in a subset of NSCLC patients and is 
indispensable for tumorigenicity and invasiveness of 
KDM2A-overexpressing NSCLC cells. The primary 
target of KDM2A-mediated repression is the dual-
specificity phosphatase 3 (DUSP3) gene, whose protein 
dephosphorylates ERK1/2.  High KDM2A levels are 
associated with low DUSP3, high phospho-ERK levels, 
and poor prognosis [192].
Therapeutic options for targeting epigenomic 
alterations are limited at this time to drugs that show little 
or no selectivity. DNA methylation inhibitors, typically 
nucleoside analogs, target DNA methyltransferases, 
leading to demethylation of DNA and gene re-expression. 
Several nucleoside analogues – 5-azacytidine and 5-aza, 
2′-deoxycytidine  –  were  found  to  be  effective  in  the 
treatment of myelodysplastic syndromes and leukemias 
and are FDA approved for these indications. Histone 
deacetylase (HDAC) inhibitors targeting acetyltransferases 
expand the repertoire of possible target genes, and several 
HDAC inhibitors have been evaluated in clinical trials 
with  encouraging  findings.    Large-scale  analysis  of 
transcriptomes  in AC  versus  SQCC  tumors  identified 
disruption of numerous histone-modifying enzymes in 
SQCC, and indicated that HDAC inhibition is a promising 
treatment strategy [193]. Phase 1/2 trial NCT00907179 
addresses the safety and efficacy of Panobinostat/LBH589 
in non-squamous NSCLC. NCT00387465, a phase 
1/2 study, explores a combination of HDAC inhibitor 
entinostat/MS-275 with azacytidine in recurrent NSCLC.
1.10. OXIDATIVE STRESS
NRF2 (NFE2L2), KEAP1, and CUL3
Nuclear factor erythroid-2 related factor 2 (NRF2 
or NFE2L2) is a redox-sensitive transcription factor that 
positively regulates the expression of various genes with 
protective function against oxidative stress (antioxidants, 
xenobiotic, detoxification enzymes and more).  Kelch-like 
ECH-associated protein 1 (KEAP1) is a ubiquitin ligase 
that negatively regulates NRF2 activity by targeting it 
for proteasomal degradation. Inactivation of KEAP1 is a 
frequent event in NSCLC [194], with mutations and copy-
number losses in ~11% of AC and 12% of SQCC cases. 
Loss of KEAP1 function is predicted to increase signaling 
from NRF2, leading to an increase in anti-oxidative 
responses and protection of cells from cytotoxic chemo- 
and radiation therapies. 
SQCC tumors have additional alterations in the 
pathway that lead to sustained signaling through NRF2, 
including NRF2 itself, which is mutated in 19% of SQCC 
tumors. Mutations are found exclusively in the KEAP1 
interacting motifs [4] suggesting that they contribute to 
the stability rather than activation of NRF2. An additional 
7% of SQCC tumors have an inactivating mutation in the 
CUL3 gene, which encodes an E3 ligase directly involved 
in degradation of NRF2. Altogether, the NRF2 inactivation 
is negatively affected in 34% of SQCC [4].  KEAP1 serves 
as an adaptor to CUL3 to initiate degradation of NRF2 
[195]. Mutations in KEAP1 and CUL3 are mutually 
exclusive with mutations in NRF2 [4]. 
Nuclear localization of NRF2 (assumed by NRF2 
protein that is not bound by KEAP1) was seen in 26% of 
NSCLCs; it was significantly more common in SQCCs 
(38%) than in adenocarcinomas (18%), and is associated 
with poor prognosis [196].
The involvement of the NRF2 pathway in 
tumorigenesis remains controversial, though mouse model 
studies indicate that in early stages of tumorigenesis NRF2 Oncotarget 1412 www.impactjournals.com/oncotarget
plays a promoting role, and its activation has been linked 
to resistance to chemotherapy (reviewed in [197]).
A recent study suggests that induction of oxidative 
stress by targeting enzyme SOD1 could be of benefit in 
NSCLC.  SOD1 inhibitor ATN-224 increases levels of 
peroxide, activates p38 pathway, and decreases levels of 
anti-apoptotic protein Mcl1, inducing regression of tumors 
in a mouse model of NSCLC [198]. 
1.11. DEVELOPMENTAL PATHWAYS
The involvement of reactivation of embryonic or 
stem cell transcriptional programs in lung cancer might 
be underestimated, since the NGS analyses are more 
geared  towards  identification  of  somatic  alterations. 
A recent study of almost 300 lung tumors identified an 
ectopic gene-expression signature associated with highly 
aggressive tumors, which was an independent predictor 
of poor prognosis. The common molecular features were 
the acquisition of embryonic stem cell/germ cell gene 
expression profiles and the down-regulation of immune 
response genes [199].
Differentiation and embryonic development related 
genes and pathways are involved in all three major types 
of lung cancer (Tables 1 and 2), and the particular genes 
affected by mutations or other alterations seem to be 
almost predetermined by the respective roles of these 
genes in development of relevant lineages. The different 
spectra of developmental pathways altered in three 
major types of lung cancer, together with the observed 
differences in disregulated epigenetic pathways, is strong 
evidence of different origins of the tumor-initiating cells 
and pathology in AC, SQCC, and SCLC. Most of these 
gene products in altered developmental pathways are 
predictably transcription factors. Unfortunately, targeting 
these is currently not approaching clinical development.  
NKX2.1 (TTF1, TTIF1)
NKX2.1 is a homeobox transcription factor essential 
for development of the normal lung, in particular in 
branching morphogenesis. NKX2.1 is amplified in up 
to 20% of lung adenocarcinoma, but not in SQCC [4, 
200, 201].  A number of targets of NKX2.1 have been 
identified, among them E2F3, cyclin B1, cyclin B2, c-Met, 
and RTK-like gene ROR1, with consequent activation 
of PI3K [202], a network of transcription factors, and 
vaccinia-related kinase VRK-1 [203].
Possible therapeutic implications of NKX2.1 
amplification  are  activation  of  ROR1  (which  sustains 
activity of c-Src), kinase activity-independent EGFR-
ERBB3 association, ERBB3 phosphorylation, and 
consequential PI3K activation [204].  As an RTK, ROR1 
could be targeted in the future. The kinase VRK-1, 
activated through NKX2.1 signaling, is also a potential 
target. 
WNT pathway
WNT signaling is involved in pathogenesis 
of  NSCLC  but  mutations  in  APC  and  β-catenin  are 
uncommon. Still, there is evidence that inhibition of WNT 
pathway in vitro inhibits proliferation of lung cancer cells 
and downregulation of WNT-pathway inhibitory proteins 
in cell lines and tumor biopsies (reviewed in [205]).   
Vanctitumab/OMP18R5, an antibody targeting frizzled 
7 in the WNT pathway, has entered clinical testing in 
NSCLC, in trial NCT01957007. 
RUNX3
RUNX3, a developmentally important transcription 
factor and tumor suppressor is often methylated in lung 
cancer [206]. RUNX3 suppresses the development of lung 
adenoma in the setting of activated KRAS, and this effect 
is mediated by RUNX3-induced expression of p14ARF 
and p21WAF/CIP [207]. These findings provide a link 
between the pathways activated by mutant KRAS and the 
p53-p14 ARF pathways.
Disrupted differentiation program in SQCC
A number of genes involved in development and in 
squamous cell differentiation were found to be mutated 
in SQCC, in 44% of samples examined.  The alterations 
include amplifications (TP63, SOX2); loss of function 
mutations in NOTCH1, NOTCH2, and ASCL4, and focal 
deletions in FOXP1 [4]. 
HMG box transcription factor SOX2 is a lineage-
survival oncogene expressed during initiation of branching 
morphogenesis in lung, but enforced high expression of 
SOX2 prevents branching and differentiation [208].   
SOX2 amplification was detected in SQCC of lung and 
esophagus, and is required for survival of SQCC cell lines 
[209]; an NGS study [4] identified SOX2 amplification in 
21% of lung SQCC.  Histone demethylase LSD1/KDM1 
was found to be significantly elevated in Sox2-expressing 
SQCC, and inhibition of LSD1 with selective inhibitor 
CBB1007 had a cytotoxic effect on cell lines with SOX2 
amplification [210].   LSD1 specifically demethylates 
histone H3K4. LSD1 inactivation directly impairs the 
Sox2-dependent transcriptional program by reducing 
the lineage-survival oncogene function and inhibiting 
Sox2-mediated repression of differentiation genes. These 
findings make LSD1 an epigenetic target for therapy in 
Sox2-expressing cancers.
A  gene  frequently  co-amplified  with  SOX2  in 
3q26 is PRKCα that phosphorylates SOX2 facilitating 
its recruitment to the promoter of Hedgehog (Hh) Oncotarget 1413 www.impactjournals.com/oncotarget
acyltransferase (HHAT). HHAT represents a rate-limiting 
step in the maturation of the Hh ligand [211].  PRKCα 
and SOX2 might act as oncogenic co-drivers in SQCC, 
as neither alone is sufficient for tumor initiation.  PKCι-
SOX2-HHAT axis contributes to the “stem-like” 
phenotype of SQCC and could be targeted with PKCα 
inhibitors or with inhibitors of HHAT that are being 
developed [212]. 
Notch signaling is required for the cell- fate 
decision between ciliated and non-ciliated secretory 
epithelium in developing lung [213]. Expression of Notch 
is associated with the stem cell compartment.  Protein-
truncating mutations of Notch receptors were reported 
in a majority of cutaneous SQCC and in SQCC of lung, 
but activating mutations of NOTCH1 commonly occur in 
human lymphoid malignancies. However, in progenitor 
basal cells of airway epithelium Notch signaling is 
required for differentiation but not cell renewal [214], 
perhaps explaining the role of abrogated Notch signaling 
in pathogenesis of lung SQCC. Inactivation of Notch is 
observed in 13% of lung SCC [4]. Notch signaling is active 
in “tumor propagating”, i.e., cancer stem cells in NSCLC 
models, and Notch3, in particular, is nonredundant in 
KRAS-driven tumors [215].  Inhibitors of β-secretase 
RO4929097, a protease needed for activation of Notch 
signaling, are in clinical trials for NSCLC, including phase 
2 NCT01193868, and in combination with erlotinib in 
NCT01193881 and with cediranib NCT01131234.
TP63 is considered to be a marker of stem cell 
compartment in different lineages, and is a regulator of 
squamous cell differentiation involved in the development 
of tracheobronchial epithelium [216]. Detection of TP63 
by immunostaining is a useful marker that distinguishes 
lung SQCC from SCLC [217].  Amplification of TP63 
was reported in SQCC-derived cell lines [218] and in 
16% of tumors [4]. An in vivo model of SQCC (not of 
lung origin) showed that TP63 signaling is essential for 
tumor growth, and identified a survival program governed 
by TP63 that involves signaling from FGFR2 activated 
by stroma-derived ligand [219]. Clinical FGFR inhibitor 
AZD4547  was  highly  efficient  in  ablating  this  TP63 
induced paracrine signaling in the mouse model. 
Truncations of ASCL4, a member of the achaete-
scute complex family of genes, were found in 3% of 
SQCC [4], and are thought to affect a developmentally 
important gene based on analogy to ASCL1, a related gene 
product essential for survival of SCLC (see below).
Involvement of developmental pathways in SCLC 
A limited number of development pathways are 
inappropriately activated in SCLC, some related to the 
neuroendocrine nature of this deadly cancer. Changes in 
expression of some key developmentally important genes 
are more characteristic for SCLC than are mutations. 
ASCL1 is a lineage-specific, basic helix-loop-helix 
member of the achaete-scute family, and it is essential for 
differentiation of numerous pulmonary neuroendocrine 
(NE) cells and tissues during lung development [220]. 
ASCL1 is highly expressed in SCLC [221]. Hes-1 is a 
transcriptional target of the Notch pathway and it blocks 
transcription of ASCL1. The Notch pathway is suppressed 
in SCLC [222], and activation of Notch signaling in SCLC 
induces growth arrest, suggesting that this pathway could 
be explored as a therapeutic target [223].
Hedgehog (HH) pathway is frequently activated 
in SCLC [224] as seen in the immunochemistry analysis 
of tumors [225].  Nevertheless, somatic alterations in 
the HH pathway have not been detected.  Deletion of 
hedgehog- signaling-molecule Smoothened (Smo) halted 
development of SCLC in a mouse model [226]. Activation 
of HH signaling after chemotherapy appears to be critical 
in development of chemoresistance, which is an inherent 
feature of SCLC. The HH pathway is a potentially 
druggable target, at least in SCLC mouse models, but it 
is unknown what specific genetic alterations in SCLC are 
associated with the activation of HH signaling.  One phase 
1 trial for SCLC is ongoing that compares chemotherapy 
alone or in combination with HH inhibitor GDC-0449/
vismodegib or with cixutumumab NCT00887159. New 
inhibitors of Hh signaling targeting enzyme HHAT are in 
development [212]. 
SLIT proteins are secreted ligands for ROBO 
receptors, which are involved in axon guidance and 
cell migration.  Robo1-deleted mice do not develop 
normal lungs and most die early after birth; survivors die 
within the first year of life and show epithelial bronchial 
hyperplasia [227].  Both SLIT2 and ROBO1 were shown 
to act as tumor suppressors in lung cancer [228, 229]. 
SLIT2 is mutated in 10% of SCLC patients [5].
EPHA7 (ephrin receptor A7) is frequently lost 
in lymphomas and other tumors and acts as a soluble 
tumor suppressor.  EPHA7 plays an important role in 
development and regulates repulsion versus adhesion of 
migrating cells, including during neural tube formation 
[230]. EPHA7 is mutated in 10% of SCLC [5].
Repositioning of antidepressants for treatment of 
SCLC.
The neuroendocrine nature of cells comprising 
SCLC tumors might offer unorthodox treatment options.   
A recent study has used a bioinformatics approach to 
identify drugs of potential benefit in treating SCLC. A 
no-longer-used class of antidepressants, tricyclics, was 
found to have a potent cytotoxic activity in SCLC in 
vitro and in vivo.  Tricyclics disrupt the autocrine survival 
signals involving neurotransmitters and their G protein–
coupled receptors [231]. On the basis of these findings, 
phase 2a clinical trial NCT01719861 examining tricyclic 
desipramine in SCLC is recruiting patients. Oncotarget 1414 www.impactjournals.com/oncotarget
1.12. OTHER RECURRENT ALTERATIONS 
The gene encoding the catalytic subunit of 
telomerase (TERT) shows copy gains in 42% of AC [2].     
The telomerase inhibitor imetelstat sodium/GRN163L 
(antisense oligonucleotide) is currently being trialed in 
breast cancer, and a telomerase vaccine GV1001 is being 
trialed in NSCLC (NCT01579188).
Even though a number of studies reported an 
association between certain polymorphisms in DNA-
damage repair genes and incidence of lung cancer, large-
scale studies have not revealed recurrent mutations in this 
group, except for ATM in AC [2]. ATM shows in-frame 
indels and truncating mutations in ~10% of AC [2]. 
SCLC cells show increased levels of PARP-
1 expression compared with NSCLC cells, and are 
significantly  more  sensitive  to  PARP-1  inhibition, 
suggesting that PARP-1 is a valid therapeutic target in 
SCLC [6]. In particular, a new PARP-1 inhibitor, BMN-
673, is highly active against SCLC in vitro and in vivo, 
but PI3K pathway activation is associated with resistance 
to BMN-673 [232]. PARP-1 inhibitors are in clinical 
testing for SCLC, either as a single agent (BMN 673 in 
phase 1 trial NCT01286987), or in combination with 
temozolomide (veliparib in phase 2 trial NCT01638546).
2. IMMUNOTHERAPY FOR LUNG CANCER 
Immunotherapy has become an exciting area 
in oncology, with new therapies directed at various 
tumors, with some early successes in particular with 
immunomodulatory antibodies. More clinical research is 
now being conducted in NSCLC. Lung cancer in general 
is not known as an immunogenic cancer, with very few 
articles  addressing  immune  infiltrates  in  lung  tumors. 
This is very much unlike the well-characterized presence 
of infiltrates in melanoma and other cancers, where they 
are  known  to  have  a  proven  predictive  significance.   
Nevertheless, early successes with immunomodulatory 
antibodies in NSCLC have been reported (see below 
and review [233]). It is already apparent that responses 
to immunotherapy, though shown to be rare in current 
studies, tend to be long lasting, unlike what is seen with 
most targeted therapies.
Experience with small-molecule targeted therapies 
across cancer types has revealed a relatively high rate of 
response of limited duration followed by development 
of resistance. Conversely, immunotherapy agents tend 
to produce responses in fairly small subpopulations of 
patients but these responses are often durable. The biggest 
challenge in developing successful immunotherapies is 
the identification of biomarkers predictive of response. 
The incorporation of immunotherapy markers into 
clinical studies is of high importance, which has been 
demonstrated in a trial of the anti-PD-1 antibody in several 
cancers [234]. Expression of the PD-1 ligand (PD-L1) was 
shown to be a very strong predictor of response in this 
study. Unfortunately, testing for predictive biomarkers of 
immune response is still in its infancy and is not always 
conducted even if a target of intervention is known (such 
as expression of PD-L1). Similarly, a vaccination trial 
could  be  conducted  with  a  defined  tumor-associated 
antigen, but its expression in a given patient’s tumor is not 
routinely examined. 
In addition, the accepted frameworks for evaluation 
of  the  anti-cancer  drug  efficacy,  Response  Evaluation 
Criteria in Solid Tumors (RECIST), and WHO 
criteria, might not be appropriate for the evaluation of 
immunotherapeutic agents, because the latter might 
produce responses that are heterogeneous and could be 
delayed or even involve an early increase in tumor burden. 
Therefore, assessment of responses to immune therapy is 
being reconsidered [235]. 
In general, immunotherapeutic approaches in 
lung cancer might have to be multi-pronged, involving 
both stimulation of immune responses and inhibition of 
immune checkpoints, or combination with chemo- or 
targeted therapies that might, in certain scenarios, increase 
the efficacy of immunotherapies. 
2.1. Blockade of immune checkpoints
Inhibition of immune checkpoints must rely on 
presence and functional activity of the tumor infiltrating 
cells (TIL). Even though immunomodulatory antibodies 
targeting CTLA4 or PD-1 interactions with its ligands 
showed promising responses in lung cancer, the non-
responsive  patients  might  benefit  from  additional 
stimulation of TILs and /or modulation of tumor 
microenvironment that dampens immune responses 
(reviewed in [236]. The role of oncogenic pathways 
in orchestrating immune escape is exemplified by the 
upregulation of PD-L1 in NSCLC with mutant EGFR 
[7]. Inhibition of EGFR enhanced T cell function and 
improved survival of tumor-bearing mice [7]. A recent 
study conducted in animal model (breast cancer) suggested 
that irradiation leads to elevated expression of PD-L1 in 
tumors and increases the efficacy of anti-PD-L1 treatments 
[237].  Observations like this may be useful in mapping 
new strategies for co-treatments with immune checkpoint 
antibodies. 
CTLA4 is an inhibitory molecule expressed on T 
cells that is involved in the negative regulation of T cell 
interaction with antigen-presenting dendritic cells (APCs). 
CTLA4 inhibits binding of CD28 on T cells to B7 proteins 
on APCs, thus weakening the costimulation of T cells. 
CTLA4 is also expressed on tumor cells [238]. Available 
results from clinical trials indicate that the response rates 
to CTLA4 blockade with human monoclonal antibodies 
ipilimumab and tremelimumab are at most 18%, but 
responses tend to be more durable than those seen with Oncotarget 1415 www.impactjournals.com/oncotarget
cytotoxic  therapies.  Significant  autoimmune  toxicities 
were reported in a number of trials, and, interestingly, 
strong association of immune-related toxicities and 
responses were observed [239].
A recent phase 2 study of chemotherapy and 
ipilimumab in advanced NSCLC showed a statistically 
significant improvement in PFS in patients initially treated 
with carboplatin and paclitaxel for two cycles; they then 
received ipilimumab with chemotherapy for four more 
cycles [240]. Overall survival was 12.2 months, similar to 
results from the combination of carboplatin, paclitaxel, and 
bevacizumab. Patients with squamous histology showed 
better response compared to those with nonsquamous 
histology. Given these results, a current phase 3 study 
(NCT01285609) will randomize 920 patients with SQCC 
to phased-in ipilimumab with carboplatin and paclitaxel 
versus chemotherapy alone. A similarly designed phase 3 
trial (NCT01450761) compares ipilimumab to placebo in 
SCLC patients receiving platinum and etoposide.  Phase 
2 trial NCT01331525 addresses the same combination as 
one-arm study for patients with extensive-stage SCLC.
Phase 1 trial NCT01820754 is currently evaluating 
the addition of ipilimumab to standard treatment for 
patients with previously untreated NSCLC.  Phase 2 trial 
NCT01471197 is comparing ipilimumab to pemetrexed in 
non-squamous NSCLC.
Ipilimumab is also being evaluated in combination 
with anti-KIR antibody BMS-986015 in patients 
with NSCKC, CRPC and melanoma in the phase 1 
trial NCT01750580. BMS-986015 targets killer-cell 
immunoglobulin-like receptors (KIR) expressed on 
natural killer (NK) cells, therefore blocking the inhibitory 
function of KIR. 
PD-1.
 PD-1 plays a major role in the tumor immune 
escape by inhibiting survival, proliferation, and immune 
function of T cells through interaction with its ligands PD-
L1 and L2.  Unlike CTLA-4, expression of PD-1 is not 
limited to T cells and is found in B cells and some myeloid 
cells. PD-1 ligands, PD-L1 and PD-L2, have different 
expression patterns, with PD-L1 found on multiple 
normal and cancerous cells including lung tumors, 
where it could provide, once bound by PD-1, peripheral 
tolerance to “self” antigens. PD-L2 is expressed on APC 
cells, providing tolerance to orally administered antigens. 
Interactions between PD-1 and its ligands attenuate 
immune responses [241], and, in the context of cancer, 
serve to protect tumor cells from cytotoxic T cells. 
Completed clinical studies of humanized antibodies 
directed against PD-1 and PD-L1 showed a good safety 
profile and remarkable antitumor activity in subsets of 
patients with metastatic disease, including lung cancer, 
which is considered to be a tumor type not responsive to 
immunotherapy. Future development of the PD-1 pathway 
blockade will have to include identification of predictive 
biomarkers of response [236]. 
In a trial for several different malignancies, anti-
PD1 antibodies were well tolerated and the maximum 
tolerated dose has not been reached [234]. This study 
found a strong correlation between pretreatment tumor 
expression of PD-L1 and responses. The better safety 
profile of PD-1 antibody versus CTLA-4 antibody is most 
likely due to the fact that the latter targets a peripheral 
interaction between T cells and APCs. Inhibition of PD-1 
probably affects peripheral interactions as well, through 
PD-L2 on APCs, but it might act more locally at tumor 
sites through blocking the interaction of PD-L1 on tumor 
cells with PD-1 in tumor-infiltrating T cells. Anti-PD-L1 
antibody was also tested in several cancers, including 
melanoma, and objective responses were observed in 9 of 
52 melanoma patients; the responses were durable [242]. 
Nivolumab (MDX-1106, BMS-936558) is a fully 
human monoclonal immunoglobulin (Ig)G4 antibody that 
binds PD-1 with high affinity and blocks its interaction 
with both PD-L1 and PD-L2. A phase 1 trial showed 
limited responses in patients with different malignancies, 
including mixed responses in one enrolled NSCLC patient 
[243]. In a phase 2 trial, nivolumab showed long-lasting, 
objective responses (OR) in patients with solid tumors – 
including NSCLC patients, of whom 14 of 76 responded 
[234].  Responses were dose-dependent in NSCLC, 
but not in melanoma or metastatic renal cell carcinoma 
patients enrolled in the trial. Expression of PD-L1 on 
available pretreatment biopsies was a predictive marker 
of response to Nivolumab. A response rate of 36% was 
observed in patients with PD-L1 positive tumors, and 0% 
in the PD-L1-negative group [234]. 
Nivolumab is currently in a number of trials in 
patients with NSCLC and two trials specifically for SQCC, 
either as a single agent or in combination with other 
targeted therapies or chemotherapy agents or ipilimumab 
NCT01454102 Combination of nivolumab and ipilimumab 
has already produced outstanding responses in patients 
with metastatic melanoma [244], and now entered trials for 
other cancers, including NSCLC NCT01928394.  Some of 
these trials include testing for PD-L1 expression in tumors, 
which have been confirmed to be predictive of responses 
to nivolumab (J Clin Oncol 31, 2013 (suppl; abstr 
3016)). Nivolumab is also being tested in a phase 1 trial 
(NCT01714739) in combination with anti-KIR antibody 
BMS-986015 and in NCT01629758 in combination with 
IL-21. The role of demethylating agents in modulating 
the response to immune-checkpoint inhibition is explored 
in trial NCT01928576; this involves pretreatment with 
azacytidine, entinostat, or CC-486 which, according to a 
recent study might sensitize NSCLC to anti-PD1 therapy 
[245].
Another anti-PD-1 antibody, MK-3475 
(Lambrolizumab), produced lasting responses in 
previously treated NSCLC patients at the rate of 24%. Oncotarget 1416 www.impactjournals.com/oncotarget
Median progression-free survival has not been reached and 
will be at least 52 weeks (15th World Conference on Lung 
Cancer, 2013). MK-3475 is currently in clinical trials for 
NSCLC, including the phase ½ trial NCT01840579 that 
will determine the MTD first, after which Lambrolizumab 
will be tested in combination with chemotherapy. The 
phase 1 trial NCT01295827 will test several doses of the 
antibody in patients with NSCLC and other cancers, and 
will also examine expression of PD-L1 in tumors, based 
on the results cited above that showed a strong correlation 
of the efficacy of Nivolumab with PD-L1 expression. MK-
3475 is also tested in phase 2/3 study NCT01905657 for 
patients whose tumors express PD-L1.
PD-L1.
BMS-936559,  a  high-affinity  human  IgG4  anti-
PD-L1 that blocks PD-L1 binding to PD-1, showed a 
promising clinical activity and good safety profile in a 
phase 1 trial, with objective responses observed in 5 of 49 
NSCLC patients enrolled [242]. This multicenter study, 
NCT00729664, is ongoing.
Other anti-PD-L1 antibodies are also in clinical 
development. MPDL3280A/RG7446 is currently 
being tested as a single-agent in two clinical trials: 
NCT01846416, a phase 2 trial for locally advanced or 
metastatic NSCLC, and NCT01375842, a phase 1 trial 
examining several different malignancies including lung 
cancer.  Preliminary results from the former trial found 
that PD-L1 tumor expression and T cell gene signature 
correlate with response to MPDL3280A. MPDL3280A 
therapy led to T-cell reactivation and restored antitumor 
immunity (J Clin Oncol 31, 2013 (suppl; abstr 3001)). The 
phase 1 trial NCT01633970 is currently evaluating the 
combination of MDLP3280A with bevacizumab (Avastin) 
and chemotherapy in patients with advanced cancers. A 
recent report (European Cancer Congress 2013, Abs. 
3048) announced that a significantly higher response rate 
to MPDL3280A was observed in smokers versus patients 
that never smoked (26% versus 10%).
Another anti-PD-L1 antibody, MEDI4736, 
entered early clinical testing recently in phase 1 trial 
NCT01693562 and phase 1 NCT02000947 in combination 
with tremelimumab (anti-CTLA-4 antobody).
Other immune therapies in development
Urelumab is a humanized agonistic monoclonal 
antibody targeting the CD137 receptor, a member of the 
TNF family of receptors, also known as 4-1BB.  It has 
potential immunostimulatory and antineoplastic activities. 
Urelumab  specifically  binds  to  and  activates  CD137-
expressing immune cells, stimulating an immune response 
– in particular, a cytotoxic T cell response – against 
tumor cells.  An agonistic antibody, BMS-663513, was in 
clinical trials for different tumors. Safety concerns caused 
suspension of the trial after several patients developed 
liver problems, including high-grade hepatitis. However, 
the antibody has a promise in expanding the repertoire of 
functional CD8+ effector cells during T cell expansion for 
autologous cell transfer (ACT). 
GITR is a costimulatory receptor expressed after T 
cell activation that enhances T cell function and survival. 
Importantly, GITR also negatively affects regulatory T 
cells (Tregs), and treatment with GITR agonistic antibody 
destabilizes intra-tumor Tregs allowing for more efficient 
cytolysis by CD8+ T cells [246]. A trial with anti-GITR 
antibody TRX-518 is ongoing in melanoma patients.
OX40 is not involved in effector T cell activation, 
but rather, promotes T cell survival and expansion. In a 
clinical study, based at the Portland Providence Medical 
Center in Oregon, patients received three infusions of 
the agonistic mouse anti-OX40 antibody within a week. 
The nature of the antibody precluded further treatments. 
Nine of 27 patients experienced minor tumor shrinkage, 
although none met RECIST (response evaluation criteria 
in solid tumors) criteria for objective responses.
CD40. Unlike the costimulatory targets above, 
CD40 is expressed on APCs, while its ligand is expressed 
on T cells. Binding of the two acts as a powerful enhancer 
of APCs’ ability to present antigens and activate T cells 
against foreign targets. A large number of cancer patients 
received infusions of agonistic antibody CP870,893 and 
some responses were observed [247]. A surprising finding 
was that treatments did not increase numbers of TILs 
in the tumors. In a mouse model, antibody treatments 
induced an influx of macrophages into tumors, presumably 
with enhanced cytotoxic activities.
2.2 Vaccine interventions
Vaccine therapy has been studied for decades in 
lung cancer, even though it is unlikely that stimulation 
(even specific) of the immune system alone could be 
sufficient to block growth of lung cancers. The concept is 
that vaccines, made from proteins drawn from tumor cells 
or from oncolytic viruses, can trigger the immune system 
to develop memory and result in long-lasting responses 
to present or future tumors. Several vaccines based on 
different antigens are in trials for lung cancer, including 
some in phase 3 [248, 249]. Antigen-specific vaccines that 
are being clinically tested include melanoma-associated 
antigen-A3, liposomal BLP-25, TG4010 (MUC-1 
based), and recombinant human epidermal growth 
factor (EGF). Other vaccines are cell-based, such as 
belagenpumatucel-L.
MAGE-A3 is an antigen present on about 35% 
of patients with NSCLC, and thus has been chosen as a 
antigen in several vaccination studies. As is often the case 
in immunotherapy trials, this strategy has shown few but 
lasting responders [250]. A phase 3 trial, NCT00480025, is Oncotarget 1417 www.impactjournals.com/oncotarget
ongoing for patients who have undergone tumor resection.   
A gene- expression signature associated with response 
to MAGE-A3 vaccination has been identified. The set 
of genes whose expression was predictive of response 
contained mainly immune-related transcripts such as in 
the interferon-gamma pathways and specific chemokines. 
This suggests that the tumor’s immune microenvironment 
plays a major role in the patient’s clinical response [251].
L-BLP25 (Stimuvax) targets the exposed core 
peptide of MUC1, a heterodimeric glycoprotein 
overexpressed in lung cancers that is also overexpressed 
in a number of epithelial cancers and is associated with 
poor prognosis. L-BLP-25 is a liposomal formulation 
of vaccine targeting MUC-1. Results from early trials 
with L-BLP25 were encouraging, but the phase 3 trial 
(Stimulating Targeted Antigenic Responses To NSCLC 
[START]) in unresectable stage 3 patients did not meet 
its primary endpoint of OS. One of the problems that 
contributed to failure could be that patients were not 
stratified based on expression of MUC-1.  A companion 
study (NCT01015443) that was being conducted in Asian 
patients (INSPIRE: Cancer Vaccine Study for Stage 
III, Unresectable, Non–small-cell Lung Cancer in the 
Asian Population) is not completed yet. A trial involving 
combination of BLP25 with Bevacizumab is ongoing for 
inoperable patients with stage 3-4 NSCLC after receiving 
chemo/radiotherapy (NCT00828009). 
Trial NCT01383148 (phase 2/3) also studies MUC-
1-based vaccine TG4010 developed on the backbone of 
vaccinia virus Ankara that was modified to express MUC-
1 and IL-2. 
rEGF.
NCT01444118 is a phase 3 trial that continues 
assessment of a vaccine composed of humanized 
recombinant EGF in hope that the immune response 
elicited will target circulating EGF in NSCLC patients and 
prevent activation of EGFR on tumors.
Telomerase.
Phase 3 trial NCT01579188 with telomerase-based 
vaccine GV1001 showed a significant increase in PFS 
in inoperable NSCLC patients who received chemo/
radiotherapy first. Increased PFS was observed only in 
patients who developed GV1001-specific T cell memory 
responses and IFNγ(high)/IL-10(low)/IL-4(low) cytokine 
profiles. The long-term follow-up of responders from the 
completed phase 2 trial demonstrated increased OS with 
some long-term responders. 
NY-ESO-1.
The DEC-205-NY-ESO-1 fusion protein vaccine, 
infused directly into lymph nodes, as a single agent or in 
combination with sirolimus is being examined in clinical 
trial NCT01522820 for various malignancies including 
NSCLC. Eligible patients are either at high risk of 
recurrence or have minimal residual disease. 
HyperAcute/Lung (tergenpumatucel-L) is a vaccine 
treatment consisting of genetically modified allogeneic 
NSCLC cells bearing alpha-(1,3)-galactosyltransferase. 
NewLink Genetics has completed phase 2 clinical study 
NCT01774578 examining tergenpumatucel-L as a single 
agent in previously treated NSCLC, where 8 of 28 patients 
had stable disease for > 16 weeks, with one patient 
surviving 50 months. Tergenpumatucel-L might also 
have a sensitizing effect on chemotherapy, since patients 
who received salvage chemotherapy after progressing 
on tergenpumatucel-L had a better overall response to 
treatments than patients who had not received prior 
tergenpumatucel-L. The trial is now recruiting patients for 
phase 3.
Indoleamine 2.3 dioxygenase (IDO).
IDO is an immune regulatory protein that suppresses 
activity of CD8+ cytotoxic T cells. Cancer cells and 
dendritic cells might produce increased levels of IDO in 
a variety of cancers. IDO is targeted using inhibitors in 
various cancers; recently a completed phase 1 vaccination 
trial (NCT01219348) showed long-lasting clinical benefits 
in almost half of patients with stage 3-4 NSCLC [252].
WT2725.
Trial NCT01621542 examines activity of peptide 
vaccine WT2725 derived from Wilms tumor protein that 
is highly expressed in a variety of malignancies. 
A pilot trial, NCT01349647, designed for patients 
with SCLC after first-line chemotherapy, will test KLH 
conjugates of GD2L, GD3L, Globo H, fucosyl GM1, 
and N-propionylated polysialic acid, with the adjuvant 
OPT-821.  The moieties used in the vaccine are known 
to be expressed in SCLC. Patients will be monitored for 
immune response and levels of CTC. 
Racotumomab is an anti-idiotype murine 
monoclonal antibody (MoAb) specific to P3 MoAb with 
anti-metastatic effect. Racotumomab binds to the idiotype 
region of P3 MoAb and functionally mimics the three-
dimensional structure of N-glycolyl ceramides of mono-
sialyl lactose, the antigenic target of P3. As a result, this 
anti-idiotype antibody may stimulate the host immune 
system to elicit humoral and cellular immune responses 
against tumor cells expressing NeuGc-GM3 gangliosides. Oncotarget 1418 www.impactjournals.com/oncotarget
A randomized phase 2 trial (NCT01240447) and a phase 
3 trial (NCT01460472) are currently being conducted in 
Cuba for patients with advanced NSCLC concomitant 
with best supportive care.  
Vaccinia-virus-based inducers.
Vaccination is currently being analyzed in 
mesothelioma patients in a phase 2 trial (NCT01569919) 
with recombinant-modified vaccinia Ankara (MVA) viral 
vector encoding the 5T4 fetal oncoprotein (MVA-h5T4) 
widely expressed in mesothelioma. The vaccine will be 
administered prior to and concomitant with the accepted 
chemotherapy regimen for mesothelioma (pemetrexed and 
cisplatin). 
Lucanix, or Belagenpumatucel-L, a vaccine 
consisting of allogeneic NSCLC cells transfected with 
an  antisense  plasmid  to  TGFα2  was  in  clinical  trials 
[253], with promising results, and is now in phase 3 trial 
NCT00676507. FANG, a new generation of cell-based 
vaccine, is an experimental autologous cell vaccine based 
on  harvested  tumor  cells  modified  to  express  shRNA 
to Furin and express GM-CSF from one vector. Furin 
suppression is expected to inhibit immunosuppressive 
signaling through its targets TGFα1 and α2. Phase 1 trial 
NCT01061840 testing FANG is designed for patients with 
inoperable solid tumors of several different histologies 
including lung. 
ISCOMATRIX.
Trial NCT01258868 is examining autologous 
tumor cell vaccination using ISCOMATRIX adjuvant 
in combination with celecoxib in patients undergoing 
surgery for lung cancer. ISCOMATRIX is a saponin-based 
adjuvant that could be combined with various antigens to 
induce antibody or T cell–based immune responses.
Dendritic cell vaccines.
An immunotherapy protocol involving metronomic 
cyclophosphamide (mCTX) followed by vaccinations with 
tumor-antigen-loaded, dendritic-cell-derived exosomes 
(Dex) is in development in France. The agent mCTX 
inhibits Treg functions, restoring T- and NK-cell-effector 
functions, and combined with Dex is able to activate the 
innate and adaptive immunity, according to the trial site 
information (NCT01159288). Phase I trials showed the 
safety and feasibility of Dex vaccines.
Autologous dendritic cells modified with adenovirus 
– employed to express chemokine CCL21 involved 
in recruitment of T cells – are used for vaccination 
of previously treated stage 3-4 patients in trials 
NCT00601094 and NCT01574222. 
Allogeneic cell vaccines.
A randomized phase 1 trial NCT01433172 will test a 
vaccine consisting of the irradiated GM.CD40L bystander 
cells  (K562  cells  modified  to  express  GM-CSF  and 
CD40L) and an equivalent number of allogeneic tumor 
cells plus or minus CCL21 involved in recruitment of T 
cells.
DISCUSSION
This review aimed to summarize the current 
understanding of molecular pathways in lung cancer, in 
particular as related to their potential to be therapeutically 
targeted.  Lung cancer is in essence a collection of 
diverse diseases, even though different histology does not 
necessarily belie different molecular blueprints of tumors, 
as is the case with large cell carcinoma. The latter was 
recently shown to belong to either AC or SCLC group, 
based on molecular alterations present in these tumors. 
Molecular blueprints of tumors are emerging as definitive 
determinants of the course of therapy to choose, even 
though presumably not all driver mutations have been 
identified in lung cancer, and many of the identified driver 
mutations are currently not targetable. 
Several oncogenic pathways are involved in lung 
cancer, but most genetic alterations (with the exception 
of TP53) are not highly recurrent in a majority of cases 
within each histological type. For example, mutations 
and translocations in receptor tyrosine kinases do not 
account for the majority of cases of adenocarcinoma.   
Nevertheless, the development of targeted therapies for the 
inhibition of the receptor tyrosine kinases has transformed 
diagnosis and treatment of adenocarcinoma, whereas 
similar advances have not yet been achieved in targeting 
alternative oncogenic pathways in other types of lung 
cancer. Tumor suppressors play a seemingly ubiquitous 
role in lung cancer, but most of them remain elusive targets 
for therapeutic intervention. Still, many of the pathways 
involved in the development and progression of lung 
cancers are currently targeted in numerous clinical trials.   
Immune therapies – in particular, blockade of immune 
checkpoints – have produced highly promising results 
in clinical studies, and will remain a subject of intense 
clinical investigations.  It is anticipated that investigational 
therapies and rational combinations thereof will lead to 
major advances in improving outcomes for patients with 
lung cancer. 
Already the development of targeted and immune 
therapies has transformed diagnosis and treatment of 
lung cancer.  Molecular testing for EGFR, EML4-ALK, 
and KRAS has become a routine diagnostic procedure in 
AC.  Other forms of lung cancer lag behind in terms of 
development of targeted therapies, but with many clinical 
trials ongoing in SCC and SCLC this is bound to change.     Oncotarget 1419 www.impactjournals.com/oncotarget
Genomic testing for personalized treatment of 
lung cancer is now associated with improved survival, 
likely due to getting targeted kinase inhibitors to the right 
patients [1]. Patients whose tumors were genotyped had 
28% better overall survival odds than those who couldn’t 
get a molecular diagnosis for various reasons. Table 3 
contains a list of drugs and their molecular targets that 
are currently in clinical testing. If even a portion of these 
drugs shows efficacy, much more effective management 
of patients based on molecular profiles of their cancers 
could be achieved. 
Rapid advances in the field of targeted therapies in 
cancer treatment might require an overhaul of the clinical 
trial system. A recent example is the “Master Protocol”, a 
new trial design resulting from a collaboration between a 
genomic testing company, federal health and regulatory 
agencies, pharmaceutical companies, multiple cooperative 
groups and patient advocacy organizations. The Master 
Protocol is a biomarker-driven, multi-drug, multi-arm, 
multi-center phase 2/3–registration trial, in which a 
comprehensive genomic testing platform will be used 
for all patients to determine stratification into appropriate 
target-specific arms of the trial. The protocol will enroll 
patients with SQCC, and could be presumably adopted for 
other types of cancer.  The use of comprehensive genomic 
testing rather than piecemeal testing for one mutation 
at a time, and the availability in the Master Protocol 
of multiple targeted drugs should greatly increase the 
probability of patients to be really matched to a targeted 
therapy. 
The problem with targeted therapies is that most of 
the time clinical responses to them are short-lived. The 
mechanisms of resistance are multifaceted, and might 
involve new resistance-conferring mutations in the target 
protein itself (such as T790M in EGFR) or activate 
lateral signal-transduction pathways via new mutations 
or changes in the expression level of the key proteins. 
The first type of resistance (“gatekeeper” mutations) is 
currently approached by development of more potent 
or irreversible inhibitors (such as CO 1686 and other 
investigational drugs for EGFR-T790M). The second type 
of resistance is addressed by simultaneous targeting of two 
or even more oncogenic proteins or pathways. 
Immune therapies, in particular immune checkpoint 
blockade, have shown a tremendous promise in clinical 
trials for lung cancer. The responses to these tend to be 
durable, but the problem is the heterogeneity of responses 
from patient to patient. A lot of effort will be expended, 
undoubtedly, into understanding the mechanisms that 
contribute to durable responses in some patients and 
lack of the responses in other patients with the same 
histological tumor subtype. It is very likely that tumor 
microenvironment and a particular genetic blueprint play 
a major role in modulation of immune responses, which 
might necessitate combination treatments involving 
targeted and immune therapies. 
Development and advancement of new treatments 
in lung cancer will depend on the widespread introduction 
of comprehensive molecular diagnostic procedures and 
encouraging patient enrollment in clinical trials; also on 
reporting and comparing outcomes. In order to address 
clinically the ever-important problem of inherent and 
acquired resistance to targeted therapies, genomic analyses 
of resistance are of utmost importance.  The success of 
immunotherapeutic approaches will depend on a better 
understanding of the basic biology of immune responses 
and, in particular, the role that tumor microenvironment 
plays in shaping immune responses. 
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